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Genetic variation has been observed in many viruses. Viruses that carry their genetic 
information in the form of RNA exhibit high mutation rates because the viral polymerase 
lacks proof-reading mechanisms commonly found in DNA polymerase complexes. The 
combination of high mutation rates, small genome size, and high replication rates results in a 
population of closely related viral genotypes, which are commonly referred to as a 
quasispecies. A consequence of the genetic variation in viruses is possible variation in viral 
phenotype of the quasispecies population. Furthermore, changes in viral phenotype may be a 
biologically important factor in progression of disease. Here, we undertook a longitudinal 
study to describe the quasispecies nature and genetic variation in a lentivirus regulatory 
protein. Rev, during the course of disease in a pony experimentally infected with equine 
infectious anemia virus (EIA V). This study examined rev variants that comprised the 
quasispecies population in sequential sera samples. Over the course of disease, there was 
continual appearance of novel rev variants, with some variants growing in frequency to 
predominate certain time points. Phylogenetic and cluster analyses suggested that the Rev 
quasispecies was comprised of two distinct populations that co-existed during infection. 
These two quasispecies populations differed in their pattern of evolution, with one population 
accumulating changes in a linear, time-dependent manner, while the other population 
evolved radially from a common variant. Changes in the population size of the two Rev 
quasispecies coincided with changes in the clinical stages of disease. Rev variants from each 
population were biologically tested, and significant differences in Rev activity were detected 
between the two populations. Together, these results suggested that the distinct Rev 
populations differed in selective advantage. A statistical correlation was found between Rev 
quasispecies activity and temperature of the pony over the course of infection. Furthermore, 
the Rev quasispecies activity differed significantly between different stages of clinical 
disease. This study suggests that distinct quasispecies populations, which differed in pattern 
of evolution and niche advantage, co-existed during long term persistent infection by EIAV. 
A multi-population quasispecies model challenges our current thinking of viral populations 
and may have significant biological implications. 
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CHAPTER 1. GENERAL INTRODUCTION 
Dissertation organization 
This dissertation describes genetic variation in the equine infectious anemia virus 
(EIAV) regulatory protein Rev, evolution of the Rev quasispecies, and the biological 
significance of Rev variation. The model for this study was that variation in Rev temporally 
modulates viral replication and contributes to viral pathogenesis and persistence. The 
dissertation is divided into five chapters, three of which are presented as papers that I have 
written. Chapter 1 is a general inu-oduction which includes an overview of host immune 
responses to viral infection, viral mechanisms for immune evasion, the quasispecies nature of 
viruses, and the role of viral variation in persistent infections. A brief inu-oduction to EIAV 
and the regulatory protein Rev are included to enhance the reader's understanding of the 
following chapters and to justify the significance of the research. Chapter 2 describes the 
genetic variation found in rev variants isolated from sequential stages of disease in a pony 
experimentally infected with EIAV. The genetic variation in rev corresponded to variation in 
Rev's biological activity, and a statistical correlation was found between changes in Rev 
activity and changes in clinical disease. I characterized the genetic variation and performed 
the statistical analyses in this study, while the biological characterization of Rev variants was 
performed by Michael Belshan. Dr. Belshan and I have organized this chapter into a paper 
and submitted it to the Journal of Virology. The statistical analysis of primer pair bias was 
summarized in the paper, and the full analysis is presented as an appendix at the end of the 
dissertation. The genetic variation described in this chapter is the basis for the other 
chapters. Chapter 3 describes a computer program written to find clusters of sequences that 
are most similar. I wrote the program using the UNIX operating system, and it was 
converted to a windows-based PC version by Olivier Fedrigo. This chapter has been 
organized into a paper and submitted to the journal Bioinformatics. This program was used 
in the genetic analysis described in the following chapter. Chapter 4 describes the genetic 
and mathematical analyses used to examine the evolution of Rev quasispecies during the 
course of infection. The results suggest that during disease, multiple Rev quasispecies 
populations co-existed and di^ered in their pattern of evolution and their selective advantage. 
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The work in this chapter has been organized into a paper that will be submitted to the 
Proceedings of the National Academy of Sciences. Chapter 5 is a general conclusion of these 
studies and their implication to studies of EIAV and viral quasispecies in general. Within the 
conclusion, future research possibilities are discussed. 
Introduction 
Persistence of equine infectious anemia virus (EIAV) infection is dependent upon 
both host and virus factors. Accordingly, this introduction includes a discussion of some host 
immune responses to viral infections and some viral mechanisms to evade the immune 
response. An important factor in immune evasion is the high mutation rate exhibited by 
viruses. The result of this high error rate, small genome size, and the rapid replication rate of 
viruses is an accumulation of related viral genomes, commonly referred to as a quasispecies 
population. A consequence of the genetic variation in viruses is possible variation in viral 
phenotype of the quasispecies population. Furthermore, changes in viral phenotype may be a 
biologically important factor in progression of disease. Experimental evidence and 
theoretical consideration of viral quasispecies are explored. The quasispecies nature of 
EIAV is discussed, and the role of Rev variation in EIAV persistence is examined. 
Non-specific immune response to viruses 
The immune response to viral infections can be classified into two main groups, a 
non-specific and an antigen-specific response. Non-specific immune responses to viral 
infection include, but are not limited to, natural killer (NK) cells and antiviral cytokines such 
as interferon (IFN). NK cells function mainly to destroy cells which are virally infected or 
altered self cells. The exact mechanisms by which NK cells recognize their target cells is 
still largely unclear. One known criterion for lysis by NK cells is the reduced expression of 
major histocompatibility complex class I molecules (MHC I) on the surface of infected or 
altered self cells (46). The MHC I molecule normally functions by presenting endogenous 
peptides on the cell surface. Cells with MHC I molecules presenting foreign (altered or viral) 
peptides are recognized and destroyed by antigen-specific cytotoxic T lymphocytes (CTL). 
Many viruses try to evade CTL lysis by decreasing presentation of viral peptides by MHC I 
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molecules on the cell surface. Reduced expression of MHC I molecules on the cell surface, 
however, makes these infected cells susceptible to lysis by NK cells. NK cells provide an 
important first line of defense since peak NK response to viral infection occurs around 3 days 
post infection (DPI), whereas antigen-specific CTL do not initiate a response to viral 
invasion until 3 DPI and do not peak until 7-10 DPI (52). 
Antiviral cytokines are another key element in the non-specific immune response to 
viral infection. Cytokines are small molecular-weight molecules that are secreted by a 
variety of cell types and serve as messengers to induce various cellular responses. A 
common cytokine released during viral infection is interferon (IFN). This cytokine can be 
secreted by T helper cells, CTL, and NK cells, and is referred to as IFN-y. Interferon 
released by leukocytes and fibroblasts are identified as IFN-a and IFN-P, respectively. 
Regardless of the cell type that secretes them, IFN targets uninfected cells and acts directly to 
induce an antiviral state in the cells. DFN induces an antiviral protein called DAI, which 
inhibits viral replication if the cell becomes infected (76). 
Antigen-specific immune response to viruses 
The main players in the antigen-specific immune response are T cells and B cells. 
The T cell population consists of T helper (T„) cells and T cytotoxic (TJ cells. The Th cells 
are crucial since they secrete cytokines that activate the cells required for an appropriate 
immune response. In a viral infection, Th cells activate Tc cells, NK cells and secrete IFN-y, 
which promotes the non-specific antiviral response described above. Antigen-specific 
activation of Tc cells induces proliferation and differentiation into effector cytotoxic T 
lymphocytes (CTL). CTL recognize and eliminate cells that present viral peptides in 
association with MHC I molecules on the cell surface. 
Activation of B cells is also involved in the antigen-specific immune response. 
Antibodies are the effector molecules secreted by activated B cells. Antibodies can bind to 
viruses and neutralize their ability to infect cells. Viral neutralization by antibodies can 
occur by preventing virus from binding to cells or preventing viral entry into cells. Most 
viruses bind to cellular receptors to begin the infection process. Antibodies that bind to or 
block the receptor binding site on the virus can prevent viral binding. In the case of human 
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rhinovirus and poliovirus, neutralizing antibodies cannot access the receptor binding site 
hidden on the virus surface, but they can still bind to regions adjacent to the receptor binding 
site and block access to the site (17, 30). Some viruses utilize a viral surface protein to bind 
to cellular receptors. Antibodies can bind directly to the viral surface protein and block 
binding, as in the case of the influenza virus (28). Other viruses, like the human 
immunodeficiency virus (HIV) and adenoviruses, can bind to cellular receptors but require 
secondary binding to co-receptors to gain entry into the cell. Neutralizing antibodies can 
block binding to the co-receptors and thus block viral entry (9, 89). 
Viral mechanisms to evade the immune response 
In order to evade the immune responses described above, many viruses have 
developed mechanisms to subvert one or more of these immune mechanisms in order to 
prolong their survival. Evasion of non-specific immune responses have been documented. 
To block the effects of IFN. members of the poxvirus family encode for soluble IFN 
receptors (2). The virally-encoded IFN receptors are secreted from the infected cell and 
competitively bind to IFN, preventing induction of an antiviral state in infected and 
uninfected cells. Cells already infected by virus may also be induced by IFN to inhibit viral 
replication. The sendai virus, however, can block the effects of IFN activation at the cell 
signaling level. Even if IFN initiates activation of the infected cell, the virus disrupts the 
complex cellular signaling pathway so that the cell cannot complete the antiviral activation 
process (50). 
Escape through viral variation 
Perhaps the most studied mechanism for viral evasion of the specific immune 
response is antigenic variation. Antigenic variation involves mutations in the epitopes that 
are recognized by CTL and antibodies. The influenza virus continually changes its surface 
proteins, hemagglutinin and neuraminidase, to evade neutralizing antibodies. The antigenic 
variation can be so great that the immune response to one influenza epidemic provides little 
or no protection against subsequent epidemics. The host range of influenza virus can also be 
expanded due to the antigenic variation, allowing cross-species infections (85). In addition. 
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the effectiveness of vaccines against the ever changing influenza virus is often minimal (18). 
The antigenic variation displayed by HIV is estimated to be 60-100 times greater than the 
influenza virus (56). Variation within the HIV genome works to diminish recognition by 
cells and CTL (37, 86). Changes in the envelope surface protein of HIV have been a well-
documented means of escaping antibody responses (55, 87,93). 
Escape through MHC I down-regulation 
Several viruses have mechanisms to escape destruction by CTL. One such 
mechanism is reduction of MHC 1 molecules that present viral peptides for CTL recognition. 
Reduced expression of the MHC 1 molecules has been observed at many different stages of 
the MHC I pathway. Oncogenic adenoviruses, for example, can down-regulate transcription 
of the MHC I genes and, thus, prevent expression of the MHC I molecules (58, 74). The 
presentation of viral peptides on MHC I molecules begins with the cleavage of viral proteins. 
Human cytomegalovirus (HCMV) and Epstein-Barr virus produce viral proteins that interfere 
with this proteolytic process (34, 54). Herpes simplex virus type 1 and type 2 encode for a 
polypeptide which inhibits the transport of cleaved viral peptides to the endoplasmic 
reticulum (ER), the location where peptides are loaded onto the MHC I molecules (83). 
Even after viral peptides have been bound to MHC I molecules, some viruses possess 
mechanism to retain or destroy these complexes. Some adenoviruses and cytomegaloviruses 
encode proteins that cause retention of the peptide/MHC I complex in the ER (1,70, 95). If 
the peptide/MHC complex does exit the ER, it can be destroyed before it reaches the cell 
surface. Both HCMV and HFV produce viral proteins that redirect the peptide/MHC I 
complex to degradation processes (47,90). 
The viral mechanism of MHC I down-regulation, however, makes these viruses 
susceptible to non-antigen-specific lysis by NK cells. Cytomegaloviruses evade NK lysis by 
encoding their own MHC I homologs that are expressed on the cell surface and serve as 
decoys for NK cells (26). Because HIV has a smaller genome, it cannot encode MHC I 
homologs. Instead, HIV evades NK cells by selectively down-regulating MHC I expression. 
The MHC is also referred to as the human leukocyte antigen (HLA) complex. HTV 
selectively down-regulates HLA-A and HLA-B but does not significantly affect expression 
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of HLA-C and HLA-E (16). It appears this partial down-regulation of MHC I is sufficient to 
protect HIV from NK cells. 
Escape through restricted viral gene expression 
In addition to down-regulation of MHC I expression, viruses can evade CTL 
responses by down-regulating expression of their own genes. The hepatitis B virus employs 
incomplete down-regulation of viral genes as one of many mechanisms to evade the CTL 
response (10). The Epstein-Barr virus (EBV) utilizes the host cell-directed methylation 
system to regulate viral gene expression (71). In this case, down-regulation of viral gene 
expression leads to long-term latency rather than rapid immune evasion. Thus, these latently 
infected cells act as reservoirs for persistent viral infection. 
Experimental evidence of viral variation 
As illustrated by the examples above, viruses exhibit a high degree of genetic and 
antigenic variation. Even before the advent of the molecular tools that currently allow us to 
determine genetic sequences, scientists have long recognized that some viruses can be quite 
variable. Some viral disease, such as measles and smallpox, can induce life-long immunity 
in those individuals that survive an initial infection. Infection by rhinoviruses and influenza 
viruses, on the other hand, generally do not impart immunity to subsequent exposures, 
indicating that some viruses can change dramatically. Furthermore, viral virulence can also 
change. Some viruses have been attenuated, through passages in unusual hosts or under 
unusual growing conditions, and used as vaccines. Even field strains of viruses can change 
in virulence. For example, the myxoma leporipoxvirus, usually lethal to European laboratory 
rabbits, was used in an attempt to control the rabbit population in AusU'alia. Initial results 
indicated high lethality (>99%), but within a year, the virulent strain had been replaced by a 
less virulent variant (27). 
With the molecular tools available today, variation in the viral genome can be 
examined on the genetic level. In addition, the mutation rate of genomes can also be 
estimated. Viruses whose genomes consist of RNA generally utilize an RNA-dependent 
RNA polymerase which is characterized by extremely high mutation rates because it lacks 
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the 3' to 5' proofreading mechanism associated with many DNA polymerase complexes (4, 
79). Thus, RNA viruses have mutation rates that are 2-4 orders of magnitude higher than 
DNA viruses, as shown in Table 1. In comparison to mammalian genomes, the mutation rate 
of RNA viruses is 6-7 orders of magnitude higher (56). Another category of viruses includes 
those RNA and DNA viruses which encode and utilize a polymerase called reverse 
transcriptase (RT) which functions as an RNA-dependent DNA polymerase. The RNA 
viruses that use RT belong to the family retroviridae. while vertebrate DNA viruses that use 
RT belong to the hepadnaviridae family. Retroviruses use RT to transcribe their RNA 
genome into DNA, which is later integrated into the host chromosome. Hepadnaviruses, a 
subfamily of DNA viruses, go through an RNA-intermediate stage before they utilize their 
RT. Since hepadnaviruses go through an RNA stage and utilize RT, their mutation rates are 
higher than other DNA viruses. 
The combination of high polymerase error rates, their small genomes, and their high 
rate of replication, results in viruses that exist as a population of related genomes. Even in 
viral populations that were thought to be clonal, genetic variation has been observed. 
Variation was detected in the viral phage QP despite the fact it had been plaque-purified 
three times (21). Stocks of equine infectious anemia virus thought to be clonal were found to 
be non-homogeneous by sequencing (53). Reversion of genetic changes has also been 
observed. A viral phage QP mutant, which had been generated in vitro by site-directed 
mutagenesis, rapidly reverted to the original variant (20, 88). Reversion in the attenuated 
Sabin poliovirus vaccine has also been observed (49). As described previously, genetic 
variation has been well documented in the influenza virus (35) and in HIV (11, 14). 
Furthermore, HIV variants isolated from serum differed from variants isolated after selection 
in cell-culture (61). Even HTV virus isolated from different infected organs differed 
genetically (91). In addition to point mutations, large size variation in viral genomes has 
been observed. During serial passage of vesicular stomatitis virus (VSV), large internal 
deletions of the viral genome can occur, resulting in defective interfering virus particles (66). 
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Table 1. Rates of spontaneous mutation per site per replication* 
Organism Mutation rate 
A. RNA viruses 
Phage QB 1.5 X 10' 
Poliovirus" 0.1-1.6 X lO"* 
Vesicular stomatitis virus 3.2 X lO"* 
Influenza virus A >7.3 X 10"' 
B. Retroviruses 
Human inmiunodeficiency virus type I 0.3-2.5 X 10-^ 
Spleen necrosis virus 0.5-3.6 X 10"^ 
Moloney murine leukemia virus 0.4->6.6 X 10 ' 
Rous sarcoma virus 4.6 X 10"^ 
C. DNA viruses 
Bacteriophage M13 7.2 X 10-' 
Bacteriophage X 7.7 X lO"'' 
Bacteriophage T2 2.7 X 10-' 
Bacteriophage T4 2.0 X 10" 
D. DNA chromosomes 
Homo sapiens 5.0 X 10 " 
Escherichia coli*' 5.4 X 10'° 
Saccharomyces cerevisiae 2.3 X 10 '° 
Neurospora crassa 2.0 X 10" 
* From Li (56) and Drake (22) 
" Excluding the case of 2.3 x 10"\ 
* Average excluding the case of 7.9 x 10"^. 
Theoretical concept of viral quasispecies 
The genetic variation within viruses results in an accumulation of related, non-
identical genomes. Eigen and Schuster first inu-oduced the term "quasispecies" to describe 
the heterogeneous viral population (24). Alternative terms that have been proposed since 
include "swarms" (81), "heterospecies", and "heteropopulations." An analytical way to 
represent the viral quasispecies is by defining a sequence space. The entire sequence space 
represents all possible sequences, and a single sequence is represented by a single point in 
this multi-dimensional space. The dimension of the sequence space is approximately equal 
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to the number of positions in the sequence. For example, the HIV genome consists of 
approximately 10,000 nucleotides. Since each nucleotide can exist as four possible bases, 
there are 4'°®" possible sequences - a number roughly equal to one followed by 6,000 zeros. 
Most of those possibilities, however, would not exist as real virus because of structural and 
functional constraints. Even if only a tiny fraction of the possible virus sequences are 
actually viable, that number is still very large. Thus, a quasispecies population in sequence 
space can be represented by a cloud of points that are clustered around a central sequence 
from which most of the other mutations arose. Like a real cloud, the quasispecies cloud does 
not need to be symmetric. There may be viral variants that extend far from the cloud center, 
on the fringe of the cloud. 
The biochemical concept of the viral quasispecies may be more familiar to 
virologists. In this framework, the quasispecies exists as a distribution of related, non-
identical nucleic acid sequences. While a quasispecies refers to the entire collection of viral 
sequences, some specific terms have been coined to describe sub-populations of a 
quasispecies. The "consensus sequence" refers to the sequence representing the "average" of 
all sequences at all positions. The "master sequence" refers to the most fit sequence. This 
term, however, is usually reserved for experiments where viral variants have been tested for 
some measure of fitness, such as ability to replicate. All other sequences that are not 
identical to the master sequence are referred to as the "mutant spectrum." Discussion of viral 
quasispecies populations is not simply on hypothetical terms, but as we have described, 
experiments have demonstrated that many viruses do exist as a quasispecies population. 
Theoretical implications of viral quasispecies evolution 
The theoretical implications of a viral quasispecies population can be sunmied up in 
terms of fimess. The biological fitness of a quasispecies is determined by the entire 
population, not just a single master sequence. The fitness of a quasispecies can be projected 
onto a "fitness landscape", as described by Wright (92). In this mathematical landscape, 
fitness is represented by elevations in the landscape, with peaks representing fimess optima 
and valleys representing low fitness (Figure I). The quasispecies resides on this fitness 
landscape, where adaptive mutations are selected and allow the quasispecies to climb up 
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Figure 1. A theoretical fitness landscape. Biological fitness is represented by elevations in 
the landscape, with peaks representing fitness optima and valleys represent non-optimal 
fitness. 
toward fitness peaks. Thus, the quasispecies is at a "selection equilibrium" (24), which is 
metastable. This means that the equilibrium will collapse when a more advantageous mutant 
arises, and a new selection equilibrium is achieved. 
The quasispecies model of virus populations can also be useful in predicting the 
effects of genetic bottlenecks on viral fitness. Genetic bottlenecks are instances where the 
genetic diversity of the quasispecies population in dramatically decreased. Most commonly, 
genetic bottlenecks occur when the quasispecies population is significantly decreased, as 
happens during viral transmission. The reduction in population size and the high rate of 
mutation will tend to incorporate deleterious changes that decrease the overall fitness of the 
population. This reduction in fitness is predicted by "Muller's ratchet", which also claims 
that compensatory mechanisms such as recombination can restore the fitness of the 
population to levels similar to the initial group of variants (63). Results of experiments with 
the viral phage 06 and VSV concur with the theory of Muller's ratchet (8, 23). After serial 
plaque-to-plaque isolations of virus, the fitness of the resulting viral quasispecies was 
significantly lower than the original quasispecies fimess. 
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The competition of variants within the viral quasispecies has also been studied, 
theoretically and experimentally. VSV clones of approximately equal relative fitness were 
used in fitness competitions. The result was that one clone eventually displaced the other 
clone (13), which was in agreement with the competitive exclusion principle of population 
genetics. The competitive exclusion principle states that in the absence of niche differences, 
one competing species will always outcompete the other (33). In competitions between 
neutral VSV clones, both the winners and the losers gained fitness relative to a reference 
clone (13). These results support the Red Queen hypothesis, which predicts that during 
competition, variants must increase in fitness just to stay in the competition (84). 
In addition to the high mutation rate of viruses, their high replication rate and 
consequently their large population size can also affect virus evolution. Domingo et al. (19) 
illustrate the effect that large population size can have on viral evolution with a 
computational model. Using a population size of 1x10^ viral particles in a genome 
distribution with an average of five mutations per genome, the expected number of genomes 
with 20 mutations is 26. If the viral population size is increased to 2x10" virions, the 
expected number of genomes with 20 mutations is 2,600. Theoretically, this means that viral 
quasispecies with large population sizes can generate a diverse population of variants that 
can adapt and evolve rapidly to the changing host environment. 
Biological significance of viral quasispecies evolution 
Apart from the theoretical implications of a viral quasispecies population, there are 
biologically significant implications of viral quasispecies. The quasispecies nature of viruses 
can lead to changes in biological phenotype of the viruses. As discussed earlier, the 
virulence of myxoma viruses infecting rabbits changed to a non-lethal phenotype (27). Even 
in the attenuated Sabin polio vaccine, variation has been observed. Virus isolated only 10 or 
28 days post vaccination from normal infants vaccinated with the Sabin type 1 vaccine strain 
were found to harbor point mutations (45). Specifically, a single nucleotide change (at 
position 472) in the Sabin type 3 vaccine was shown to occur regularly and was associated 
with a definite increase in neurovirulence (25). In addition, one or a few mutations have 
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been attributed to changes in virulence of avian, human, and swine influenza virus (39.48, 
77). 
The genotypic and phenotypic variation in viral quasispecies can also play a role in 
viral persistence. Variants with lower virulence have been observed during the prolonged 
asymptomatic stage of HIV infection (40,44). Genetic variation and the quasispecies nature 
of foot-and-mouth disease virus are also thought to contribute to persistence (82). An 
important biological consequence of the quasispecies nature of viruses includes persistence 
of viruses through evolution of drug-resistant variants. Even in the face of active antiviral 
drug therapy, HIV, hepatitis B, and herpes virus have evolved drug-resistant variants (38,41, 
65). 
Variation in EIAV Rev and its role in persistence 
EIAV 
Equine infectious anemia virus (EIAV) belongs to the lentiviridae subfamily of the 
virus family retroviridae. Other members of the lentivirus subfamily include the human, 
simian, bovine, and feline immunodeficiency viruses (HIV, SIV, BIV, and FTV, 
respectively), caprine arthritis encephalitis vims (CAEV), and visna virus. EIAV possesses 
two copies of single-stranded (+) sense RNA which contain the genetic information for the 
vims. The RNAs and viral enzymes are packed within a capsid to form the core of the 
virion. Surrounding the core is a protein matrix, which is covered by a lipid envelope 
through which project viral envelope proteins (Figure 2A). EIAV preferentially infects ceils 
of the monocyte/macrophage lineage (12, 68). Infection of these cells is thought to involve 
interaction between the viral surface protein and one or more cellular receptors. The specific 
cellular receptor(s) required for EIAV binding and entry, however, have not yet been 
identified. Once inside the host cell, the matrix and capsid core of the virion disassemble, 
and the viral polymerase, called reverse transcriptase (RT), converts the single-stranded viral 
RNA into double-stranded DNA. The viral DNA is transported into the nucleus, where it is 
integrated into the host cell genome. In this integrated pro viral form, the virus can stay 
dormant for long periods until transcription is initiated by binding of cellular transcription 
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Figure 2. Retrovirus virion and replication cycle. A. Retrovirus virion and its 
components; (SU) surface protein, (TM) transmembrane protein, (RT) reverse transcriptase, 
(IN) integrase, (NC) nucleocapsid, (CA) capsid, (PR) protease, (MA) matrix. B. Retrovirus 
replication cycle. The cycle begins with viral binding and entry of the host cell, reverse 
transcription of the viral RNA, nuclear localization, and integration into the host genome. 
Cellular activation leads to transcription of viral mRNA, some of which are spliced, exported 
out of the nucleus, and translated into viral proteins. The viral genome and structural 
proteins assemble near the cell membrane and bud from the cell, becoming mature virions. 
These figures were taken from (15). 
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exported out of the nucleus and into the cytoplasm. Some of these mRNAs serve as the new 
virus genome, while other mRNAs produce viral proteins, including the structural proteins. 
These viral proteins and RNA assemble near the cell surface and bud from the cell surface, 
taking with it some of the cellular membrane (Figure 2B). 
EIAV infects members of the family Eqiiidae and causes a persistent, life-long 
disease. The clinical signs of disease include but are not limited to anemia, fever, 
thrombocytopenia, and weight loss (reviewed in (43)). In a classical EIAV infection, horses 
experience an acute febrile episode within one to two weeks post infection. The acute 
disease is followed by a period characterized by recurring cycles of fever and 
thrombocytopenia, possibly accompanied by anemia and weight-loss. Each febrile episode is 
associated with high levels of virus replication, and new antigenic variants have been found 
in different febrile cycles (43, 51). The frequency and severity of the clinical cycles 
eventually declines over time until the horse becomes clinically inapparent. Even though 
horses appear clinically normal at this stage, they remain seropositive carriers of the virus for 
life. Although the virus titer is much lower in comparison to febrile horses, inapparently 
infected horses can act as a reservoir, and transmission of EIAV from these animals under 
field conditions to uninfected horses is possible (42,43). 
Host immune response against EIAV 
Both the cellular and humoral immune response against EIAV contribute to 
suppression of viral replication during inapparent stages of infection (36. 75). EIAV-specific 
CTL have been observed 2 to 4 weeks post infection (32, 60) and generally coincide with 
resolution of the initial viremia but are not correlated with resolution of further episodes of 
viremia (36). Some speculate that the rapid CTL response helps to temporarily stem the viral 
infection, allowing the humoral response time to respond effectively (96). EIAV envelope-
specific IgM has been detected in serum 3 weeks post infection, with envelope-specific IgG 
following 7 to 10 weeks post infection. Neutralizing antibodies are detected approximately 2 
or 3 months post infection and weeks after the initial febrile episode had been resolved (36). 
Full maturation of the humoral response to EIAV is not usually established until 6 to 8 
months post infection. In most cases, neutralizing antibodies are effective only against 
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homologous viraJ strains, and little or no cross-neutralization is observed between different 
isolates of EIAV (62.67). Thus, no subset of the immune response has been shown to 
specifically correlate with control of virus replication during long term persistent infections 
(36). 
EIAV persistence 
The quasispecies nature of EIAV has been well documented (5, 7, 53, 59). While 
genetic variation occurs throughout the EIAV genome, three regions of hypervariability have 
been observed: the viral long terminal repeat (LTR), the surface envelope (SU), and a region 
where the major exon of Rev is completely overlapped by the transmembrane protein (TM) 
(3, 7, 57). The antigenic variation caused by genetic variation in structural proteins is a well-
studied mechanism of EIAV persistence. New antigenic variants have been observed in 
different febrile episodes, concurrent with periods of high viremia (43, 51). Variation in the 
surface envelope and transmembrane proteins can result from point mutations, insertions, or 
duplications. These changes can alter viral antigenicity and contribute to evasion of host 
immune responses during infection (72, 73, 75). 
Recent studies suggest that genetic variation in the EIAV LTR and other regulatory 
proteins may contribute to viral persistence through down-regulation of viral gene expression 
(7, 53, 57). The LTR contains the only viral promoter region and the transcription start site 
for the virus. In vivo variation has been observed in the EIAV LTR which altered 
transcription factor binding sites (7). Ablation of transcription factor binding sites may 
contribute both to changes in the level of virus gene expression during the course of infection 
and changes in cell tropism (57). Genetic variation in the regulatory gene, rev, has been 
observed both in vivo and in vitro (3, 53). Since Rev facilitates the shift to expression of 
viral structural genes and is absolutely required for replication, changes in rev may alter viral 
gene expression and viral replication rales (5). Thus, genetic variation in the LTR and the 
regulatory protein Rev may contribute to EIAV persistence. 
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EIAV Rev function 
EIAV encodes for the regulatory proteins Tat and Rev, which are the first viral 
proteins made from the initial multiply-spliced mRNA. The main function of Rev is to 
facilitate the shift from the early expression of regulatory gene to the late expression of 
structural genes, which is absolutely required for viral replication. Rev accomplishes this 
function by exporting the incompletely-spliced mRNA which encode for structural proteins 
or serve as the new viral genome. EIAV Rev is functionally homologous to HIV-1 Rev (31). 
and its Rev-mediated nuclear export pathway is based on that of HIV-1 Rev (Figure 3). 
Figure 3. Mechanism of Rev-mediated nuclear export function. The process of Rev 
expression begins in the nucleus with (1) transcription of the proviral DNA to make the 
mRNA, (2) splicing of the mRNA by the host spliceosome which produces a (3) four-exon, 
bi-cistronic mRNA that is (4) exported out of the nucleus. The bi-cistronic mRNA encodes 
for two regulatory proteins, Tat and Rev. Rev functions by (5) localizing into the nucleus. 
(6) binding the Rev responsive element (RRE), (7) multimerizing, and (8) utilizing the 
CRMl nuclear export pathway to export the incompletely-spliced mRNA which encode viral 
structural proteins and serve as the new progeny RNA. 
(j2 
AAAA 
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According to the HTV-l pathway. Rev re-enters the nucleus, binds a secondary sUiicture in 
the viral pre-mRNA called the Rev responsive element (RRE) (94), multimerizes (69), then 
utilizes the CRM I nuclear export pathway to redirect movement of incompletely-spliced 
RNA out of the nucleus (6, 29, 78, 80). Distinct domains have been identified for each of 
these functions in HIV. Currently, only the nuclear localization signal (64) and nuclear 
export signal (31) have been identified in EIAV. 
Overall goal 
The regulatory protein Rev plays an important role in the replication cycle of EIAV. 
Attenuated Rev phenotypes have been detected in long term non-progressor HIV-1 patients 
who have been infected over ten years without progressing to AIDS (40,44). Genetic 
variation in the major exon of EIAV rev has been observed(3, 53), and limited genetic 
variation in rev can also alter the biological activity of Rev (5). Together, these facts have 
led us to the hypothesis that genetic and biological variation in the Rev quasispecies 
differentially regulates the expression of viral genes in vivo and contribute to the variable 
disease course in EIAV-infected animals. To test this hypothesis, we have undertaken the 
following specific aims: 
The Specific Aims are: 
1. Identify predominant rev variants at sequential time points following infection and 
determine the biological activity of those variants. (Chapter 2) 
2. Use/develop genetic and mathematical tools to analyze the evolution of rev 
quasispecies. (Chapter 3 and 4) 
3. Determine whether there is a correlation between Rev quasispecies activity and 
clinical signs or stages of disease of EIAV. (Chapter 2) 
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CHAPTER 2. SEQUENCE VARIATION IN EQUINE INFECTIOUS ANEMIA 
VIRUS REV CORRELATES WITH VARIABLE STAGES OF CLINICAL DISEASE 
IN AN EXPERIMENTALLY INFECTED PONY 
A paper submitted to the Journal of Virology 
Michael Belshan'\ Prasith Baccam'J. Lindsay Oaks\ Brett A. Sponseller', 
Sean C. Murphy', James L. Comette" and Susan Carpenter' 
Abstract 
Genetic and biological variation were examined in the regulatory protein Rev of 
equine infectious anemia virus (EIAV) throughout a dynamic disease course of an 
experimentally infected pony. The pony underwent a variable disease course, including an 
acute fever episode at 12 DPI, multiple recurrent fever episodes until 135 DPI, a prolonged 
subclinical period, and two late fever episodes. Viral RNA was isolated from the inoculum 
and sequential sera samples, and the rev exon 2/gp45 overlapping ORFs were amplified, 
cloned, and sequenced. Novel variants were found throughout infection, and genetic analysis 
indicated that both the rev and gp45 ORFs were under selective pressure. The Rev variant 
predominant in the inoculum, Rl, remained predominant during the early periods following 
infection (until 35 DPI). However, Rl was replaced by new predominant variants during the 
recurrent fever period (67-135 DPI). Rl re-emerged as the predominant variant during the 
afebrile period. However a new predominant variant. R93, was associated with the late 
fever episodes. In vitro analysis of Rev-mediated nuclear export activity indicated the 
predominant variants present during clinical periods were significantly more active than the 
variants predominant during the acute and afebrile periods. Statistical correlation was found 
between Rev activity and different stages of clinical disease. Together, these results suggest 
that sequence variation in rev may be a contributing factor of EIAV pathogenesis. 
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Introduction 
Equine infectious anemia virus (EIAV) possesses common features of the 
Lentiviridae subfamily of retroviruses, including a complex genome organization, tropism for 
cells of the monocyte/macrophage lineage, and establishment of a persistent, lifelong 
infection. Many lentivirus infections are characterized by a slow, chronic disease, but 
infection of horses with EIAV can result in an acute, dynamic disease course. EIAV 
infection can result in recurring cycles of viremia, fever, and thrombocytopenia, with a 
possible development of anemia (reviewed in (20)). Fever cycles are typically irregular and 
may last for up to one year, despite the onset of a neutralizing antibody response. Horses 
which survive these initial clinical episodes become life-long, inapparent carriers of the virus. 
Virus persistence over a life-long infection is dependent upon both host and virus 
factors. Genetic variation in Antiviruses, the result of errors produced by reverse 
transcriptase, is a well-studied mechanism of lentivirus persistence (19, 23, 34, 38). Three 
regions of hypervariability have been observed in EIAV: the viral long terminal repeat 
(LTR), the surface envelope (SU), and a region where the major exon of Rev is completely 
overlapped by the transmembrane protein (TM) (1, 6, 31). Variation in the surface envelope 
protein, due to mutations, insertions, or duplications within the principal neutralization 
domain or hypervariable region, can alter antigenicity and facilitate evasion of host immune 
responses (21. 25-27, 33, 39-42,45,53). Studies examining the immune responses of EIAV-
infected horses indicate that both cellular and humoral immune responses contribute to 
suppression of virus replication during inapparent stages of infection (12,45). However, no 
subset of the immune response has been shown to specifically correlate with control of virus 
replication during long term persistence (12). Therefore, other host and virus factors may 
contribute to the severity of clinical disease, virus persistence, and pathogenesis. 
Control of lentivirus replication involves viral regulatory proteins. Variation in 
regulatory elements may alter the level of virus gene expression and subsequently viral 
replication. The role of regulatory protein variation in viral persistence has been, for the 
most part, unexplored. Genetic variation in the second exon of the EIAV regulatory protein 
Rev has been previously described (1,3,28). Rev functions to facilitate the nuclear export of 
the incompletely spliced viral RNAs during the late phase of virus replication. These viral 
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RNAs encode the structural proteins and serve as progeny RNA molecules. Rev-dependent 
RNA export pathways have been described for numerous lentiviruses (reviewed in (8, 16)), 
and the human immunodeficiency virus type 1 (HTV-l) Rev export pathway is the best 
characterized. HIV-1 Rev binds a structure in the viral pre-mRNA called the Rev-responsive 
element (RRE) (52), multimerizes (37), then utilizes the CRMl nuclear export pathway to 
redirect movement of incompletely spliced RNA from the nucleus (5,9,47,48). Discrete 
functional domains within Rev that mediate its interaction with cellular proteins and viral 
RNA are required for nuclear localization, RNA binding, multimerization and nuclear export. 
EIAV Rev is a 165 amino acid protein functionally homologous to HTV-l Rev (10). The 
major exon encodes for the nuclear export signal of EIAV Rev, amino acids 1-25 (10), and 
has been shown to be able to substitute for the HIV-1 or visna virus effector domains (10. 
29). A putative nuclear localization signal has been mapped to the arginine rich C-terminus 
ofEIAVRev(13). 
Rev is absolutely required for expression of structural genes and production of new 
virus. Therefore, factors which modulate Rev activity and, consequently, alter levels of viral 
gene expression may be important in regulating virus replication in vivo. Rev-attenuated 
phenotypes have been identified during asymptomatic stages of HIV-1 infection, suggesting 
that variation in Rev could alter virus replication levels and contribute to the clinical outcome 
of infection (17, 22). We previously identified extensive nucleotide substitutions in the 
second exon of EIAV rev in virus obtained from an experimentally infected horse (1). The 
co-existence of putative Rev-competent and Rev-deficient phenotypes suggested that 
variation in Rev may contribute to viral persistence through regulation of viral replication. 
Subsequent in vitro analysis indicated that limited amino acid variation in Rev could alter 
biological activity (3), further suggesting variation in Rev may modulate virus replication 
during disease. 
The present study characterizes genetic and biological variation in the major exon of 
EIAV rev during a long-term study of an experimentally-infected pony. Sequence analysis 
indicated a constant but dynamic evolution of rev throughout disease. An in vitro assay of 
Rev-mediated nuclear export demonstrates that Rev variants predominant in the recurrent 
and late fever periods displayed significantly higher nuclear export activity than variants 
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predominant in the inoculum and in the afebrile period of disease. Statistical correlation was 
found between Rev activity at different time points and temperature of the pony. 
Furthermore, Rev activity in the acute febrile and afebrile stages of disease differed 
significantly from Rev activity in the recurrent febrile stage of disease. These findings 
strongly argue that variation in rev is an additional factor contributing to the pathogenesis of 
disease caused by EIAV. 
Materials and methods 
Experimental infection. The experimental infection of pony 524 has been 
previously reported (36). The pony was infected with 10' horse infectious doses of the 
highly virulent Wyoming strain of EIAV (EIAVwyo)- Physical examinations, rectal 
temperatures, hemograms, and platelet counts were performed daily during clinical episodes 
and intermittently during chronic clinical disease or subclinical infection. Serum and plasma 
were collected, processed, and stored at -80°C until analyzed. 
Virus neutralization assay. Assays were performed using equine dermal (ED) cells 
maintained in Dulbecco's modified eagle medium (DMEM) supplemented with 20% fetal 
bovine serum, penicillin, and streptomycin as previously described (7). ED cells were seeded 
one day prior to infection at 10^ cells/well in a 6-well dish. Serum from pony 524 was heat 
inactivated at 60°C to destroy complement and serially diluted two-fold in supplemented 
media. Five hundred focus forming units of EIAV^ju-s in a 100 ^.1 volume was incubated 
with 100 ^1 of serially diluted pony 524 serum at 37°C for 1 h. Duplicate wells of ED cells 
were inoculated with 100 ^1 of virus-serum mixture in the presence of 8 ^g/ml polybrene, 
and the following day the media was changed. Cells were incubated for an additional 72 h, 
fixed with 100% methanol, and immunocytochemistry performed using convalescent anti-
EIAV horse sera to detect foci of vims-infected cells (7). Results are expressed as the serum 
neutralization titer, defined as the reciprocal of the highest serum dilution that gave an 80% 
reduction in foci as compared with pre-immune and negative control serum. 
Isolation of viral RNA. EIAV^yo inoculum was obtained as a serum sample 
collected from an experimentally-infected foal at 7 days post-infection (DPI). To obtain viral 
RNA, 100 jil of EIAV^yo inoculum or pony 524 serum was pelleted by centrifiigation at 
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93,000 X g for 1 h at 4°C. Viral RNA was isolated from these pellets by guanidine 
thiocyanate lysis and acid phenol-chloroform extraction using a commercially available kit 
(Ambion, Austin, TX) and resuspended in 24 ^il RNase-free glass distilled water containing 
0.1 mM EDTA. 
Amplification and sequence analysis of viral variants. RNA samples were DNase 
treated using the methods of Huang et al. (18). Briefly, two units of DNase I (Ambion, TX) 
were added to 3 ^1 of viral RNA, 20 mM MgCU, 1 mM of each dNTP, IX PCR buffer 11 
(Perkin-Elmer, Branchburg, NJ), 20 units of RNase inhibitor, and 2.5 mM of random 
hexamers in a total volume of 20 |j,l. The reaction was incubated at 37°C for 30 min and 
heated to 75°C for 5 min to inactivate the DNase. After cooling to 4°C, 50 units of Moloney 
murine leukemia virus reverse transcriptase were added. Reactions were incubated at 42°C 
for 45 min, heated to 99°C for 5 min to inactivate the reverse transcriptase, and then cooled 
to 5°C for 5 min. The reaction was brought up to 100 |il in IX PCR buffer II with 2 mM 
MgCl,, 0.2 mM of each dNTP, 2.5 units Taq polymerase (Perkin Elmer), and I |iM of each 
primer. Primers were designed based on conserved regions flanking the second exon of rev 
(Table 1). PCR amplification conditions consisted of 37 cycles of denaturation at 94°C for 2 
min, annealing at 50°C for 1 min, and extension at 72°C for 1 min. The initial and final 
cycles contained a prolonged extension at 72°C for 5 min. 2 (il of PCR product was TA-
cloned into pGEM-T vectors as recommended by the manufacturer (Promega, Madison, WI) 
and transformed into Escherichia coli DH-5a. Positive clones were identified by colony blot 
hybridization using a subgenomic fragment of rev labeled with ["P]dTTP by random primed 
labeling (Roche Molecular Biochemical, Indianapolis, IN). Plasmids were isolated from 
positive clones using a conmiercially available kit (Promega), and the rev inserts were 
sequenced bi-directionally with vector primers flanking the insert. All sequencing was 
performed by the Iowa State University DNA Synthesis and Sequencing Facility using an 
automated DNA sequencer. Sequences were aligned by MacVector and AssemblyLIGN 
software (Oxford Molecular, Beaverton, OR). To estimate the RT-PCR error rate, viral 
mRNA isolated from a clonal cell line stably transfected with an EIAV proviral DNA clone 
was reverse transcribed and amplified with Taq polymerase. The ampiicons were cloned and 
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17 individual clones were sequenced. The error rate of the RT-PCR amplification procedure 
was determined to be 0.025%, or 3 substitutions per 11.991 base pairs sequenced. 
Construction of Rev expression vectors, rev variants were subcloned into 
pERevWT, a Rev expression vector previously described as pcH2l (3). This plasmid 
contains Rev cDNA in the pCR3 background (Invitrogen, Carlsbad, CA). pERevWT was 
digested with the restriction endonuclease Apal to remove rev exon 2. The digested plasmid 
was gel purified, dephosphorylated, and ligated with the exon 2 sequence variants. Two 
methods, based upon the direction of the inserts in pGEM-T, were employed to move variant 
exon 2 sequences into the pERevWT background. Inserts in the "forward" direction were 
digested with Apal, gel purified, and ligated into the digested pERevWT background. Inserts 
in the "reverse" orientation were PCR amplified with the EM7160 primer and a 3' EIAV 
primer containing an Apal site (underlined): 5'-
CTGGGCCCTCATAAATGTTTCCTCCTTCGC. The PCR products were purified, 
digested with Apal. and ligated into the pERevWT background. All clones were verified for 
directionality by resuiction mapping and confirmed by sequencing. 
Statistical analyses. A two-dimensional chi-square test was used to test the null 
hypothesis that the frequency distribution of observed variants and the choice of primer pairs 
was independent. The chi-square statistic was calculated, and the p-value was determined for 
each contingency table. The statistical threshold used in this study was 95% confidence. 
Subset pairwise analyses were also performed on the data, and the results were interpreted 
with Bonferroni's correction (32). For the Monte Carlo simulation (44) comparing the four 
primer pairs, the chi-square distance was calculated between the four sets of simulated data. 
The data was simulated 10,000 times, and experimentally observed chi-square distances were 
compared with the 10,000 simulated distances to find the percentile ranking, which correlates 
to the p-value. For the pairwise analyses of primer pairs, 10 variants were randomly created 
for each set of the two simulated primer pairs. The remainder of the simulation was the same 
as described immediately above, except the Kullback distance (4) was calculated rather than 
chi-square distance. 
The transition to transversion ratio and the non-synonymous to synonymous mutation 
ratio were calculated using the program SITES, version l.l (15). The Tajima test (51), 
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which determines whether variation within a region of nucleotides was due to selective 
pressure or neutral mutations, was also performed using SITES. 
The experimental Rev quasispecies activity (RQA) for each time point was calculated 
as the average Rev activity of tested variants, weighted by frequency of the variants, as 
illustrated in the following equation: 
Iv, •" 
1=1 
where n is the number of different variants tested, v, is the number of times variant i was 
detected at that time point, and A, is the Rev activity level for variant /. A phylogenetic tree 
was constructed, and untested variants were assigned the same activity as the nearest tested 
variant in the tree. The predicted Rev quasispecies activity was estimated in the same way as 
the experimentally Rev quasispecies activity, except n is the index for all variants at the 
given time point. The statistical package SAS, version 6.03 (46), was used to examine 
possible correlation between the experimental and predicted Rev quasispecies activity and 
different signs of clinical disease. Pearson correlation was used to test virus titer, platelet 
counts, and temperature of the infected pony. A quadratic model was used to fit the 
relationship between Rev quasispecies activity and temperature, and analysis of the 
studentized residuals was used to test the quadratic model. Comparison of Rev quasispecies 
activity between different stages of disease was done by using a general linear models 
procedure, adjusted for multiple comparisons by Tukey-Kramer correction. 
Quantification of virus load. RNA quantification standards were synthesized by in 
vitro transcription from a linearized plasmid containing a 450-base pair fragment of EIAV 
gag (pEIAp26.1). The RNA was purified by extraction with Trizol Reagent, treated with 6 
units of DNase I (Ambion) for 45 min at 37°C to remove plasmid DNA, and then extracted 
again with Trizol Reagent. Final RNA preparation was quantified by spectrophotometry, 
aliquoted, and stored at -80°C. The absence of contaminating plasmid DNA was verified by 
PCR without reverse transcription. 
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To create standards, known copy numbers of RNA standards were assayed in 
triplicate as described below; tiiese included 2 x 10\ 2 x lO^ 2 x 10\ 2 x lO"*, and 2 x 10^ 
copies of RNA. Reaction products were visualized in ethidium bromide-stained agarose gels, 
and their densities quantified using a commercial digital imaging system (IS 1000, Alpha 
Innotech). The mean density for each copy number was plotted against the log,o of the copy 
numbers used to construct a standard curve. 
The one tube, semi-quantitative RT-PCR protocol was modified from that described 
by Hamel et al (11). The reaction buffer contained 50 mM KCl, 10 mM Tris (pH 9.0), 0.1 % 
Triton X-100, and 2.0 mM MgCK, and each reaction contained 0.4 mM deoxyribonucleotide 
mix (Roche Molecular Biochemicals), 1 unit of RNase inhibitor (Roche Molecular 
Biochemicals), 20 units of Moloney Murine Leukemia Virus reverse transcriptase 
(superscript H, Gibco BRL, Rockville, MD), 1.5 units of Taq DNA polymerase (Gibco 
BRL), and 90 pmoles of the forward primer (5'- ACTACTTGGGTGAATACCAT) and 90 
pmoles of the reverse primer (5'- TCTGCCTAAACTGATCAAAA) in a final volume of 
25|il. These oligonucleotides prime both reverse transcription as well as the subsequent PGR 
reaction, and amplify a 322 base pair segment of the EIAV capsid protein gene {p26) (nt 897-
1199). Amplification was performed as follows: 42°C for 40 min, DNase I inactivation at 
95''C for 3 min, and 40 cycles of 94°C for 30 s, 58''C for 30 s, and 72°C for 30 s. Each RT-
PCR run included positive and negative controls. Complete removal of all DNA from 
samples was confirmed by performing a duplicate reaction without reverse ttanscriptase. 
Following amplification, 13|liI of the PGR reaction was analyzed by electrophoresis through 
2.0% agarose and visualized by ethidium bromide staining and ultraviolet light. Serum 
samples from each time point were assayed in duplicate, and their mean density values were 
used to calculate copy numbers of viral RNA from the standard curve. RT-PCR reactions for 
standards and samples were performed simultaneously using a reagent-master mix, and were 
analyzed simultaneously in a single agarose gel. 
CAT Assays. 293 cells were maintained in Dulbecco's modified eagle medium 
supplemented with 10% fetal calf serum and penicillin/streptomycin. Transient transfections 
and CAT assays were performed using 293 cells as previously described (3). Briefly, l^ig of 
either pcDNA3 or Rev variant plasmid was transfected by calcium phosphate co-
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precipitation with 0.2 ^ig of pERRE-All reporter piasmid, 0.2 ^g of pCHl 10 (Amersham 
Pharmacia Biotech, Piscataway, NJ), and 0.6 |ig of pUCl9. pERRE-All, a derivative of 
pDM138 containing EIAV nt 5280-7534, has been described previously (3). Each 
experiment also included a sham group which contained no reporter piasmid, but an 
additional 0.2 |ig of pUC19. Two days post-transfection, cells were harvested, resuspended 
in 0.3 ml 0.25 M Tris (pH 7.5), lysed by freeze/thawing, and assayed for P-galactosidase 
activity to normalize CAT assays for transfection efficiency. Normalized lysates were 
assayed for CAT activity in a O.l ml volume with 3|il ['^C]chloramphenicol and 1 mM acetyl 
CoA. Acetylated products were separated by thin layer chromatography and the percentage 
of acetylation determined by quantification by phosphoimager. Experiments were performed 
in triplicate and results summarize a minimum of nine independent transfections. Statistical 
significance was determined by analysis of variance. 
Results 
Clinical profile of EIAVwyo'infected pony 524. To accurately reflect the diversity 
of an in vivo infection, pony 524 was inoculated with the highly virulent Wyoming strain of 
EIAV (EIAVvk,yo), which has been maintained by serial in vivo passage (36). This inoculum 
represents a heterogeneous population of virus, similar to a natural infection. After 
inoculation, pony 524 experienced a clinical disease course characterized by recurring fever 
cycles interspersed with afebrile periods ranging from days to months (Fig. I A). The initial 
acute episode included a bi-phasic febrile response and thrombocytopenia from 10 to 22 days 
post infection (DPI). The pony was then afebrile until 39 DPI. Thereafter, pony 524 
underwent a period of seven recurrent fever episodes, which ranged from two to six days in 
length. The last fever episode ended after day 135, and pony 524 remained afebrile except 
for two late fever episodes at days 565 and 799. Febrile episodes were defined as rectal 
temperature greater than or equal to 101°F. Thrombocytopenia (platelet count less than I x 
10^ pIatelets/^1) was also observed concurrent with the initial fever cycles. After the initial 
fever cycles subsided, pony 524 remained persistently thrombocytopenic throughout the 
experiment. Except for the fever and thrombocytopenia, no other clinical signs were 
observed. 
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Semi-quantitative RT-PCR was used to monitor virus levels at various DPI (Fig. IB). 
Consistent with previous reports, high virus loads were found in the initial fever period at 12 
DPI, but fell to a nearly undetectable level during the afebrile interval at 35 DPI. The highest 
virus load, 9.08 x 10^ copies RNA/ml, was detected during the recurrent febrile period at 67 
DPI. Levels of plasma viral RNA decreased somewhat in the subclinical period and were 
barely detectable at 754 DPI. However, virus rebounded to 1.38 x lO' copies/ml at 800 DPI. 
Serum neutralization assays to EIAV^su-S' a cell culture derived strain of (35), 
indicated that broadly reacting neutralizing antibodies appeared after the chronic fever cycles 
subsided (201 DPI) (Fig. IC). Pony 524 maintained elevated neutralizing antibody to 
EIAVwsu.5 throughout the remainder of the experiment. 
Quasispecies distribution of the inoculum and statistical analysis of sampling 
procedure. The overall goal of these studies was to examine rev variation at successive 
stages of clinical disease. A potential problem with current methods used to characterize 
viral variants is the possible selection of a sub-population of variants that may not be 
reflective of the population present in vivo. To confirm that the selected primer pairs did not 
bias the distribution of observed variants, statistical analysis was performed on the 
distribution of variants obtained by RT-PCR amplification of the inoculum. Sequences were 
amplified using four different sets of primer pairs, designed from conserved regions flanking 
exon 2 of rev. A total of 61 individual clones, at least ten from each primer pair, were 
sequenced from the EIAV^yo inoculum. Thirty-eight different genotypes and 25 different 
Rev amino acid variants, designated R1 through R25, were observed (Fig. 2). Five 
genotypes were observed at a frequency greater than one. and two clones. R1 and R2, 
accounted for 30% and 25% of the sample population, respectively. These results indicated 
that the distribution of rev genotypes in the inoculum was not uniformly random. Chi-square 
analyses found no significant bias due to primer pair choice. Thus, the observed quasispecies 
population is reflective of the in vivo population. 
Genetic changes in revlgp45. To analyze rev variation throughout infection, RNA 
was isolated from the inoculum and firom sera samples collected at various stages of clinical 
disease including: Acute febrile (12 DPI), first afebrile interval (35 DPI), recurrent febrile 
(67, 89, and 118 DPI), afebrile (201,289, 385, and 437 DPI), and late febrile (754 and 800 
39 
DPI) periods. The rev exon 2lgp45 overlapping region of EIAV was amplified using primer 
pairs 2 and 3, and twenty-two to twenty-six individual clones were sequenced at each time 
point. Sequences from each time point represent data from two independent RT-PCR 
reactions. Novel variants were detected at each time point; however, the appearance of new 
variants was more rapid during clinical periods (Table 2). The greatest number of new 
variants for both rev and gp45 was observed at 67, 89, 118, and 201 DPI, corresponding to 
the recurrent fever period and the first sample of the afebrile period. Conversely, fewer 
novel genotypes were observed at 289, 385,437, and 754 DPI, periods of sub-clinical 
infection. 
The region of EIAV analyzed contains two overlapping ORFs that encode for Rev 
and TM, and a variety of genetic analyses were used to evaluate the significance of genetic 
changes in each reading frame. Consistent with observations of other retroviruses (24), 
genetic analysis of the nucleotide sequences found a high ratio of transition (Ts) to 
u-ansversion (Tv) at each time point. In addition, there was a high ratio of non-synonymous 
(N) to synonymous (S) mutations in both ORFs of the overlapping region (Table 2). The 
overall N/S ratio greater than one for both rev (1.54) and gp45 (2.15), suggesting that 
variation in this region was due to selective pressure. The Tajima test (51) is a widely used 
procedure to determine whether nucleotide variation within a region is due to selective 
pressure or to neutral mutations. Application of the Tajima test confirmed that this region 
was indeed under selective pressure. Together, these data indicate a continuing evolution in 
rev and gp45 throughout infection, with changes due to selective pressure in both reading 
frames. 
Rev variation throughout clinical disease. The genetic analyses suggested that 
variation in rev was due to selection rather than neutral mutations. Because of the key role 
which Rev plays in viral replication, we focused our analyses on variation in the rev ORF. 
Rev amino acid sequences were examined from the inoculum (Fig. 2) and at each time point 
(Fig. 3). As described above, the inoculum was predominated by two amino acid variants, 
R1 and R2, which accounted for 30% and 25% of the sample population, respectively. The 
consensus sequence for the inoculum was identical to the sequence of RI. Genetic variation 
in the inoculum was not detected uniformly across Rev, and there were two main regions of 
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variability. Amino acid position 25, located at the C-terminus of the nuclear export signal, 
was highly variable, with either a consensus serine or a leucine at that position. Another 
region of variability occurred at aa 104-108, which had a GDYQQ consensus sequence while 
a small number of variants had a DGYQR at these positions. The consensus sequence of Rl 
was used as the standard by which the subsequent sera samples were compared. 
Acute stage. During the early period after infection, there were no changes in the 
consensus sequence. The Rev quasispecies found in the initial febrile episode at 12 DPI was 
genetically very homogeneous, and Rl remained the predominant variant, accounting for 
75% of the sample population. All other variants differed from Rl by a single amino acid, 
and none of the variants contained changes at aa 25 or in the GDYQQ region at 104-108. In 
the intervening afebrile episode that followed at 35 DPI. the observed variants resembled the 
inoculum population. Variant R2 was detected along with Rl, and the latter was again the 
predominant variant at 35 DPI. As in the inoculum, genetic variability was detected at 
position 25 and the DGYQR motif in region 104-108. 
Recurrent febrile stage. The Rev quasispecies populations observed in the recurrent 
febrile period (67,89, 118 DPI) were markedly changed from the previous populations, as 
re f l ec t ed  i n  a  new consensus  s equence  a t  each  t ime  po in t  (F ig .  4 ) .  No tab ly ,  t he  va r i an t  R l ,  
which predominated the inoculum as well as in samples from 12 and 35 DPI, was not 
detected in any of the three samples taken during the recurrent febrile stage. Variants which 
were present as minor populations in earlier time points increased in frequency to 
predominate the three time points examined. For example, the variant R32 was a minor 
variant at 35 DPI but grew to predominate the population at 67 DPI. The consensus 
sequence at 67 DPI was identical to R32 and had an alanine at aa 82 as well as the DGYQR 
motif in the region 104-108. R32 was also detected at 89 DPI, however, no variants 
accounted for more than 20% of the population at this time point. The consensus sequence at 
89 DPI consisted of the G and R in the DGYQR motif and was represented by the variant 
R12. R53 was present as a minor variant at 89 DPI and grew to predominate the quasispecies 
population at 118 DPI. R53 shared the consensus sequence at 89 DPI and also possessed a 
lysine at aa 97 in addition to the GYQR motif at aa 105-108. Thus, the recurrent febrile 
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period was characterized by continual changes in the consensus sequence, with minor 
variants growing to predominate at subsequent time points 
Afebrile stage. The first serum sample analyzed after the recurrent febrile episodes 
subsided was obtained at 201 DPI. No variant accounted for more than 20% of the 
population at this time point. Interestingly, after going undetected throughout the recurrent 
febrile period, R1 was observed as a minor variant. The consensus sequence at 201 DPI was 
unlike those previous observed. The sequence of R78 was identical to the consensus 
sequence at 201 DPI and consisted of an aspartic, lysine, and arginine at aa 80,97, and 108, 
respectively. During the remainder of the afebrile period (289, 385 and 437 DPI), the 
frequency of R1 grew to predominate, and the consensus sequence was identical to R1 at 
each time point. The minor variants did not change much during the afebrile stage, with 
R17, R32, and R33 observed in most of the samples. In contrast to continual appearance and 
growth of minor variants in the recurrent febrile stage, the variants found in the afebrile stage 
appeared to be relatively more stable. 
Late febrile stage. Two late fever episodes occurred at 565 and 799 DPI. Analysis 
of rev variation included samples collected at 754 and 800 DPI. A new variant, R93, arose as 
the predominant variant and consensus sequence at 754 and 800 DPI. Although R1 was 
observed as a minor variant at 754 DPI, it was not detected at 800 DPI. The consensus 
sequences for both 754 and 800 DPI differed from R1 by 7 amino acids. At position 25, 
where an S or L had previously been observed, a proline was the consensus residue. An 
alanine at position 75 was also a novel change. The aspartic, lysine, glycine, and arginine at 
positions 80,97, 105, and 108, respectively, which had been part of earlier consensus 
sequences, were again in the consensus sequence for 754 and 800 DPI. 
In summary, the dynamics of the Rev quasispecies evolution were reflected by the 
changes in the consensus sequences during the course of disease (Fig. 4). These changes 
may be exemplified by the disappearance and reappearance of Rl, which was identical to the 
consensus sequence in the acute fever episode and the intervening afebrile period, but was 
replaced by novel variants during both the recurrent and late febrile periods. The changes in 
rev consensus sequences coincided with changes in the different stages of clinical disease 
and may reflect the different selective pressures present at each stage of disease. 
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Biological activity of Rev quasispecies. Earlier work in our lab had shown that 
genetic changes in rev can alter Rev's biological activity (3), and it was important to 
determine the biological effect of Rev variation observed in this study. Rev variants which 
appeared at a frequency >20% of the population or representative of consensus sequences at 
any time point were cloned into eukaryouc expression vectors containing rev exon I. 
Additional variants were selected for biological comparisons. The Rev-mediated nuclear 
export activity was determined in transient transfection assays as previously described (3) 
and were normalized to Rl. R2, a variant which contained a single L25S change from R1 
exhibited a similar level of activity to Rl. The variant R26, which was detected at 12, 118 
and 754 DPI, was the only variant tested that had significantly lower Rev activity (63%) than 
Rl. Interestingly, ail other variants assayed showed significantly higher levels of nuclear 
export activity in comparison to Rl (p<0.05). These included variants that were identical to 
the consensus sequences during the recurrent febrile and late febrile stages (67, 89, 118, 754, 
800 DPI). The consensus sequences represented by the variant, R12, R32, R53. and R93. all 
exhibited approximately 165% activity relative to Rl. Other variants tested from the 
recurrent febrile stage, R42, R45, and R51, also had Rev activity approximately 175%. The 
sample at 201 DPI was characterized by the co-existence of Rev variants with low activity, 
Rl and R2, and variants, R71 and R72, which had relatively higher activity. Thus, it appears 
that day 201 post infection represents a transition between the recurrent febrile and afebrile 
stages of disease. In summary. Rev variants observed during the recurrent and late febrile 
periods possessed significantly higher biological activity than sequences in the acute fever 
episode and the afebrile period. These results strongly suggest that changes in Rev 
phenotype may be associated with changes in clinical disease stage. 
Rev quasispecies activity. As our data have shown, rev variants existed as a 
quasispecies population. Since no one variant can deHne the phenotype of the quasispecies, 
we attempted to calculate an average phenotype for the Rev quasispecies at each time point. 
The variants experimentally tested accounted for at least 50% of all clones observed at each 
time point. The activity of the tested variants was used to calculate the experimental Rev 
quasispecies activity at each time point (Table 3). Since it was not feasible to biologically 
assay all observed variants, a phylogenetic tree was constructed using the Rev amino acid 
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sequences to examine the reiatedness of the variants (not shown). We observed that variants 
that were close together in the tree had similar Rev activity. For example, R12, R53, R71, 
and R72 were clustered together in the tree, and they all had similar Rev activity around 
160%. Therefore, the untested Rev variants were each assigned the same Rev activity as the 
nearest tested variant, and a predicted Rev quasispecies activity was estimated (Table 3). 
The statistical package SAS, version 6.03 (46), was used to examined possible correlation 
between the experimental and predicted Rev quasispecies activity and different signs of 
clinical disease. 
Statistical correlation. Pearson correlation coefficients were calculated to test for 
correlation between the Rev quasispecies activity and various clinical parameter, such as 
virus titer and platelet counts. No statistical correlation was found with either the 
experimental or predicted Rev quasispecies activity (p>0.l9). Analysis by Pearson 
correlation found that the temperature of the horse was statistically correlated with the 
experimental (p=0.007) and predicted (p=0.011) Rev quasispecies activity (Fig. 5B). The 
relationship between Rev quasispecies activity and temperature were modeled by a quadratic 
model (p=0.0001). Because the changes in Rev genotype and phenotype appeared to 
coincide with changes in the stages of clinical disease, the Rev quasispecies activity was 
tested against the different stages of disease (acute febrile, recurrent febrile, afebrile, and late 
febrile stage). The experimental and predicted Rev quasispecies activity of the acute febrile 
stage differed significantly from the Rev quasispecies activity of the recurrent febrile stage 
(p=0.0I3 and p=0.014, respectively) (Fig. 5B). Comparisons of experimental and predicted 
Rev quasispecies activity between the recurrent febrile stage and the afebrile stage were also 
significant (p=O.OlO and p=0.015, respectively) (Fig. 5B). No significance was detected in 
the remaining comparisons. The results of the correlation analyses for the experimental and 
predicted Rev quasispecies activity provide strong evidence that genotypic and phenotypic 
variation in Rev is correlated with progression of EIAV disease. 
Discussion 
Antigenic variation has long been recognized as an important mechanism of lentivirus 
persistence and pathogenesis. Recent studies suggest that variation in viral regulatory 
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elements, including the LTR and accessory genes, also contributes to clinical disease (3, 6, 
17,28, 31). We previously observed a high degree of genetic variation in the rev exon 
2lgp45 region of EIAV (3, 28) and demonstrated that limited amino acid variation in Rev 
alters biological activity (3). It has been proposed that attenuation of Rev phenotype may 
allow EIAV to persist through down-regulation of viral gene expression and reduced 
replication (3). To delineate the significance of rev variation in vivo, we have examined 
sequence variation in an experimentally-infected animal. Genetic variation observed in rev 
during sequential stages of EIAV infection clearly demonstrated that rev variants exist as a 
quasispecies population. Genetic analysis demonstrated that the rev ORF evolved throughout 
infection and that variation was due to selective pressure rather than neutral mutations. The 
frequency at which new variants were detected was greatest during clinical periods, 
concomitant with higher levels of virus replication at these times. Rapid and dynamic 
changes in Rev quasispecies coincided with changes in clinical disease. Rev variants which 
were predominant during the recurrent febrile episodes had significantly higher nuclear 
export activity than the variants predominant during the acute febrile or afebrile periods. 
Statistical analyses found that Rev quasispecies activity was correlated with the temperature 
of the infected pony. Additionally, Rev quasispecies activity in the acute febrile and afebrile 
stages were significantly different from the Rev quasispecies activity in the recurrent stage of 
disease. Together, these findings argue that variation in rev is a contributing factor of EIA 
disease pathogenesis. 
The rapid and dynamic evolution of Rev quasispecies during sequential stages of 
clinical EIA is exemplified by the changes in the frequency and distribution of Rl. This 
variant, and the closely related R2, clearly represented the predominant genotype and 
phenotype in the inoculum and during the early time period following infection. At 
subsequent febrile periods, Rl was replaced by series of closely related Rev variants with 
significantly higher biological activity. Surprisingly, Rl reappeared and predominated 
during the prolonged afebrile period, yet was replaced by the more biologically active R93 
during the late febrile period. The predominance of Rl during the acute febrile period 
suggests that Rl is a robust phenotype, capable of supporting high levels of virus replication. 
Indeed, its overall predominance throughout the afebrile period suggests that Rl is a stable. 
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functional Rev genotype. The high level of Rev activity during the recurrent febrile periods 
may indicate that the host environment at that stage requires highly active Rev variants to 
maintain high levels of virus replication. Further studies to identify virus and host factors 
which contribute to selection of R1 and other Rev variants will provide insight into factors 
which contribute to EIA pathogenesis. 
Viremia has long been associated with clinical episodes in EIAV-infected animals 
(20). The abrogation of recurrent clinical episodes is typically co-incident with the 
maturation of the host immune response and decline in virus replication (12). The 
appearance of broadly acting neutralizing antibody in pony 524 at 201-289 DPI was 
associated with the resolution of the febrile period; however, we did not observe the expected 
drop in virus load during much of the prolonged afebrile period, and viremia remained high 
until late in the afebrile stage of disease (754 DPI), despite the re-emergence of the less 
active RI at 201 DPI. As suggested above, Rl is a fully competent Rev able to support high 
levels of virus replication. It is possible that Rev variants less active than Rl might have 
been detected if pony 524 had resolved to a clinically inapparent state in which virus load 
decreased to near undetectable levels. Perhaps the Rev quasispecies activity may be 
statistically correlated with virus load if pony 524 had become clinically inapparent. 
It is generally accepted that sequence variation in overlapping reading frames is much 
more constrained than variation in sequences with a single ORF. However, a previous report 
examining human immunodeficiency virus type 1 (HIV-1) variation in the revlgp41 
overlapping ORFs suggested that despite such constraints, both genes evolved independently 
(30). Our data would suggest the opposite for the EIAV rev/gp45 overlap. Several lines of 
evidence support this hypothesis. First, the evolution of both ORFs was surprisingly similar 
throughout infection. The rate of appearance of new rev and gp45 variants was most 
frequent in both ORFs during periods of high virus replication. Second, out of 146 nt 
variants, there was a similar number of total Rev and gp45 aa variants (101 and 105, 
respectively). Third, the overall diversity (number of aa variants at each time point) of rev 
and gp45 was approximately the same throughout infection. Finally, with the exception of 
35 DPI, each predominant Rev variant was associated with a corresponding gp45 variant. 
The only evidence that would suggest a divergent evolution is the fact that at seven of the 
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eleven time points, there was a higher increase in the number of new rev variants than gp45 
variants. Therefore, we argue that the evolution of rev and gp45 is convergent, and we 
cannot rule out that changes in gp45 also contribute to the selective advantage of the 
observed Rev variants. Hence, variation in both regions may be an important determinant of 
virus pathogenicity in vivo. 
The underlying assumptions of the RT-PCR method are that all viral quasispecies are 
amplified with equal efficiency, and the resulting proportions are representative of the 
starting population. While these assumptions have generally been accepted, some reports 
suggest that PCR amplification might result in selective amplification of individual 
templates, especially in reactions containing a heterogeneous population of templates (2,43, 
49, 50). Previous studies have suggested that interactions between primers and templates 
might alter the efficiency of template amplification and thus alter the sample population (2, 
14, 50), or that primer pairs may systematically bias PCR amplification (2,43, 50). 
However, these studies have generally involved 2 or 3 different templates of known 
concentrations. The complex nature of viral quasispecies in vivo can further complicate 
sequencing studies. Our statistical analysis of primer pair bias in the inoculum overcomes 
such complexities and shows that the frequency of observed variants was not altered during 
PCR amplification. The risk of bias may have been reduced by designing primers to 
conserved target sequences and using primers with similar GC-content and optimal annealing 
temperatures. Taken together, our results suggest that randomly sampled viral populations 
obtained by RT-PCR can reflect in vivo populations. This offers confidence in the 
characterization of viral quasispecies present in vivo and strengthens interpretations of 
studies examining the role of virus variation in immune evasion and disease progression. 
Many previous in vivo studies of EIAV variation have used a cloned, cell-culture 
propagated virus as an inoculum. Such an inoculum typically represents a homogenous 
population of virus. While such studies have been useful in identifying genetic changes that 
arise during an in vivo infection, our intention was to better reflect a naturally occurring 
infection in an experimentally-infected animal. Therefore, the inoculum used was obtained 
from a donor pony undergoing its first fever cycle and represented a heterogeneous 
population of virus instead of a single clone. Although this method required a more 
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extensive analysis, we believe it provided an accurate representation of the complex nature of 
EIAV evolution throughout disease. The heterogeneous nature of the inoculum, in 
combination with the extensive genetic analysis at sequential lime points, allowed us to 
examine the genetic variants that made up the rev quasispecies and the biological phenotype 
of the Rev quasispecies that were selected at variable stages of clinical disease. It is clear 
from this study that genetic and phenotypic changes in the Rev quasispecies were associated 
with changes in clinical stages of disease. The corresponding changes in the activity of the 
Rev quasispecies during the recurrent febrile stage provides strong evidence that variation in 
Rev can confer a selective advantage in vivo. 
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EM 7066 CAAITTGGCACAATCCATGA 40 
I EM 7674C GCGAGAGTTCCTTCTTGGGC 60 55.7 
EM 7066 CAATTTGGCACAATCCATGA 40 
T EM 7680CR1 GGAATTCCGAGAGTTCCTTCTTGG 50 55.7 
EM 7160 GGATTGGGAGCTTCCATTAT 45 
3 EM 7674C GCGAGAGTTCCTTCTTGGGC 60 55.5 
EM 7160 GGATTGGGAGCTTCCATTAT 45 55.5 
4 EM 7680CR1 GGAATTCCGAGAGTTCCTTrTTGG 50 
indicates the primer is on the complementary (anti-sense) strand, and RI indicates the 
presence of an £coRI restriction site (underlined) at the 3' end. 
Optimal annealing temperature for PCR amplification in °C, as determined by the program 
Oligo 5.1 (Plymouth, MN). 
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Table 2. Genetic analysis of variation in rev and gp45 ORFs 
DPI 
•NOC 12 35 67 89 118 201 289 385 437 754 800 Total 
61 24 23 23 24 24 25 22 26 23 24 23 322 Clones 
#Variants 25 7 11 13 18 11 16 8 12 6 7 8 
Rev New 25 6 7 9 14 8 12 3 7 1 5 4 101 
Variants 
Kn/Ks'' 1.0 0.9 7 2.2 2.6 1.9 2.4 1.8 2.1 1.5 2.0 1.2 1.5 
#Variants 30 7 ID 14 16 11 15 8 10 12 8 11 
gp4S New 30 5 4 11 12 7 10 2 4 6 5 9 105 
Variants 
Kn/Ks'' 2.3 1.2 2.2 4.0 1.8 1.9 4.2 3.2 2.1 14 3.4 7.7 2.1 
^ Ratio of non-synonymous to synonymous mutations in that ORF 
TABLE 3. Rev activity of variants, experimental and predicted Rev quasispecies activity. 
Rev Var. Rl R2 R4 R12 R17 R26 R32 R42 R45 R51 R53 R7I R72 R86 R93 
Rev Acl.* 100 96 222 169 131 63 176 138 193 180 165 162 154 131 153 
DPI b leslvd/iotar ERQA" PRQA* 
AC 
12 18 0 0 0 0 1 0 0 0 0 0 0 0 0 0 19/24 98 98 
35 6 2 0 0 2 0 2 0 0 0 0 0 0 0 0 12/23 117 124 
67 0 0 0 1 2 0 10 1 1 0 0 0 0 0 0 15/23 169 170 
RF 89 0 0 0 2 1 0 4 3 0 1 1 0 0 0 0 12/24 166 165 
118 0 0 0 2 0 2 0 0 0 0 12 0 0 0 0 16/24 153 158 
201 3 4 0 0 1 0 1 0 0 0 0 2 4 0 0 15/25 129 136 
AF 
289 9 4 0 0 2 0 1 0 0 0 0 0 0 0 0 16/22 108 117 
385 II 4 0 0 0 0 1 0 0 0 0 0 0 2 0 18/26 107 108 
437 II 4 0 0 1 0 4 0 0 0 0 0 0 0 0 20/23 116 120 
LF 
754 4 0 0 0 0 6 0 0 0 0 0 0 0 0 10 20/24 115 122 
800 0 0 0 0 0 0 0 0 0 0 0 0 0 1 16 17/23 152 151 
" The activity level of each variant tested, relative to the activity of Rl. 
The days post infection from which the variants were isolated and the stage of disease (AC = acute febrile, RF = 
recurrent febrile, AF = afebrile, LF = late febrile). 
The number of clones tested and the total number of clones at each time point. 
** The experimental Rev quasispecies activity calculated for each time point. 
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Figure 1. Clinical and serological profile of pony 524. (A) Clinical profile of EIAV^yo-
infected pony 524. Platelet counts (gray line, primary y axis) and fever episodes (columns, 
secondary y axis) were monitored as described in Materials and Methods. Fever was defined 
as rectal temperature greater than or equal to lOTF. (B) Virus load, as measured by copies 
of RN A/ml serum, was determined by semi-quantitative RT-PCR for the days indicated by 
open circles. (C) EIAV^su-s neutralizing antibody (VN) titers of pony 524. VN titers were 
determined as described in Materials and Methods from serum samples obtained at 0. 11. 35, 
67, 89, 118, 201, 289,498, 754, and 800 DPI. 
Figure 2. Frequency and distribution of Rev aa sequences in EIAVwv„ inoculum. 
Twenty-five variants were obtained from 61 total clones sequenced. The frequency (N) and 
variant identity (V) are given. The aa sequence of the dominant variant (Rl) is given, and 
the changes in amino acid sequence in all other variants is shown. (.) Indicates an identical 
aa to Rl at that position and (-) indicates a -1 frameshift mutation. 
Figure 3. Alignment of Rev aa sequences obtained from sera of pony 524 at 12,35,67, 
89,118,201,289,385,437,754, and 800 DPI. The frequency (N) and variant identity (V) 
are given for each time point, as well as the total number of clones sequenced (below the N 
column). Dominant variants are highlighted in bold. Sequences are compared to Rl, which 
is listed at the top of each time point. For individual sequences (.) indicates an identical aa to 
Rl at that position, (*) indicates a premamre stop codon in the rev ORF, and (+) indicates a 
+ 1 frameshift. 
Figure 4. Consensus Rev aa sequences at each time point (DPI). The variant identity (V) 
and sequence, relative to Rl is given for each time point. At two time points, 89 and 201 
DPI, no variant was predominant and the consensus sequence was represented by a minor 
variant, indicated by (*). 
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Figure 5. Rev-mediated nuclear export activity of Rev variants and variation in EIAV 
Rev correlates with temperature and clinical disease. (A) In vitro biological activity of 
Rev variants from pony 524. Rev exon 2 variants were inserted into a eukaryotic expression 
vector and transient transfection assays were performed in 293 cells as described in the 
Materials and Methods. CAT assays were normalized to the activity of R1 and the results are 
presented as a percentage of activity compared to Rl. Error bars denote the standard error of 
the mean. Variants that differed significantly from the activity of R1 are indicated, with p-
values represented by (*) p<0.05, (**) p<0.005, and (***) p<0.00005). (B) The rectal 
temperature of pony 524 along with the predicted (open circles) and experimental (closed 
circles) Rev quasispecies activity at each time point. Statistical correlation was found 
between Rev quasispecies activity and temperature of the pony (p<0.02). The Rev 
quasispecies activity in the acute febrile stage, 12 and 35 DPI, and afebrile stage, 201, 289, 
385, and 437 DPI, were significantly different from the Rev quasispecies activity in the 
recurrent febrile stage, 67. 89, and 118 DPI, of disease (p<0.02). No statistical differences 
were found between the late febrile stage and any other stages of disease. 
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CHAPTER 3. CAGE: CLUSTER ANALYSIS OF GENETIC EVOLUTION 
A paper submitted to Bioinformatics 
Prasith Baccam'Robert J. Thompson" \ Olivier Fedrigo^, 
Susan Carpenter^"', and James L. Comette' 
Abstract 
Motivation: The complexities of genetic data may not be accurately described by any single 
analytical tool. Phylogenetic analysis is often used to study the genetic relationship among 
different sequences. Complex evolutionary models and assumptions are invoked to reconstruct 
the bifurcating branches that connect the sequences within a phylogenetic tree. Genetic 
databases are rapidly accumulating large amounts of sequences. Newly acquired sequences, 
which have not yet been characterized, may require preliminary genetic exploration in order to 
build models describing the evolutionary relationship among sequences. There are clustering 
techniques that do not assume any models of evolution, and thus may provide useful 
exploratory tools for identifying genetic similarities. Some of the more commonly used 
clustering methods perform better when data can be grouped into mutually exclusive clusters. 
Genetic data from viruses, for example, may consist of closely related variants that differ by 
small changes and may best be grouped by overlapping clusters. 
Results: We have developed an intuitive exploratory program. CAGE, which clusters 
sequences that are genetically similar. CAGE was used to analyze the data set of Shapshak et 
al. which consisted of human irrnnunodeficiency virus type 1 envelope sequences isolated from 
different regions of the brain. The results of CAGE were in agreement with phylogenetic 
analysis of the same data. CAGE provides an additional tool which can be used to glean 
information from genetic data and can be used in conjunction with other tools to study genetic 
similarities and genetic evolution. 
Availability: http://www.vetmed.iastate.edu/units/carplab/CAGE/main.html 
Contact: pbaccam@iastate.edu 
' Department of Mathematics, Iowa State University 
- Department of Veterinary Microbiology and Prevenuve Medicine, Iowa State University 
^ Interdepartmental Genetics Program, Iowa State University 
Department of Zoology and Genetics, Iowa State University 
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Introduction 
The rapid accumulation of genetic data resulting from high-throughput sequencing and 
the various genome sequencing projects necessitates a variety of computer programs to analyze 
the genetic data. Phylogenetic programs like PHYLIP (5) and PAUP (15) have been 
increasingly utilized to analyze the evolutionary relationship among genetic sequences. Genetic 
conversions and recombinations, however, may not be modeled well under the bifurcating 
assumptions of phylogenetic tree construction. Progress is being made on inferring genetic 
relationships when recombination has occurred. Some examples of these methods include 
spectral analysis (1), split decomposition (3), and median networks (7). Another method of 
finding similarity among sequences is to describe the multidimensional information in low 
dimensions. Examples of this method include principal components analysis (PCA) (12), 
principal coordinates analysis (PCOORD) (6, 8), and multivariate statistical sequence analysis 
(16). Some data sets, however, may not be analyzed well by this method as the best 3-
dimensional representation of the data may not capUire even the majority of information in the 
data set. In addition, the algorithms used to reduce the dimensionality of the data set may be 
non-intuitive to some users, and the results of the analysis may likewise be non-intuitive. 
The program described here. Cluster Analysis of Genetic Evolution (CAGE), is an 
intuitive tool that allows the user to explore genetic data and identify groupings of sequences 
that are most similar. The program's intuitive nature comes from the fact that it does not 
assume complex models of evolution like some of the methods mentioned previously. The 
number of clustering techniques currently available is large, but the number of clustering 
programs for analyzing sequence data seems to be limited. Hierarchical methods of clustering 
are popular, partly because dendograms can be produced from the clustering process. Of the 
methods that group by hierarchical techniques, the unweighted pair-group method using 
arithmetic averages (UPGMA) method (11) is one of the most widely used. Other hierarchical 
techniques include single linkage (SLINK) (14), complete linkage (CLINK) (10), and Ward's 
method (17). These hierarchical methods all belong to the category of agglomerative methods, 
because they begin with a cluster for each element and reduce the number of clusters by 
merging one cluster to another cluster. 
The agglomerative clustering methods are similar to CAGE in the fact that they do not 
rely on evolutionary models to cluster the data, but there are some marked differences between 
CAGE and the agglomerative methods. The agglomerative methods merge data together to 
form clusters which grow larger in a process termed "chaining". This chaining process can 
identify mutually exclusive clusters but may have difficulty with overlapping clusters. Viruses 
exist as a heterogeneous population of closely related variants, commonly referred to as a 
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quasispecies (2,4,9), and may not be grouped appropriately by mutually exclusive clusters. 
Because it allows for overlapping clusters, CAGE may perform well with viral data or with 
sequences that behave in a quasispecies nature. CAGE is designed to group sequences by 
using spherical clusters which are defined by a radius parameter. By repeatedly increasing the 
radius value, analysis by CAGE can produce hierarchical clusters. This program is not meant 
to replace phylogenetic analysis or the other methods mentioned above, but it offers an 
alternative exploratory tool for investigating genetic similarity. 
Systems and methods 
CAGE was written in ANSI C-H- and can be compiled and operated on Macintosh. PC, 
and UNIX platforms. The input file should consist of aligned nucleotide or amino acid 
variants. The most basic measure of genetic distance, nucleotide or amino acid change 
(referred to as genetic change hereafter), was used to define the distance between all sequences. 
After the input file is opened, the user has the option to consider or ignore gap positions in the 
distance calculations. A genetic distance matrix is created, where entries represent the number 
of genetic differences between all pairwise sequences summed across the entire sequence, also 
known as a Hamming distance. After all the pairwise sequence distances are calculated, the 
distances are sorted. If there are distinct, non-overlapping clusters, there may be regions of 
genetic distances which are not present in the sorted distances. The program identifies the 
largest such region, which may serve as a good radius value to begin searching for clusters. 
The remainder of the program is menu-driven and offers the following options: 
1. Display the genetic distance matrix 
2. Display the clusters for a range of radius values 
3. Display the clusters for a single radius value 
4. Search a cluster for sub-clusters 
5. Display a rearranged genetic distance mauix 
6. Display all potential clusters for a single radius value 
7. Display the average distance fi-om all centers in a range of radius values 
8. Display all genetic distance from a single sequence 
9. Display the genetic distance between two sequences 
Algorithm 
The basic assumption of the program is that sequences separated by the fewest genetic 
differences are more similar and should cluster together. A radius is selected by the user, and 
each sequence is used as a center to define spherical clusters. From all the potential clusters 
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centered around each sequence, options 2-5 utilize an algorithm which automatically identifies 
all distinct clusters (clusters containing more than one variant and not a subset of other 
clusters). The center genotype of each cluster is the sequence that is most representative of all 
variants within the cluster. The first distinct cluster is the cluster that contains the most variants 
within the cluster. If more than one cluster contains the same number of variants, then the 
cluster that is the most "compact" is chosen. Compactness is characterized by having more 
variants surrounding the center rather than near the boundaries of the cluster. Computationally, 
the most compact cluster minimizes the average distance between the center and all other 
variants within the cluster (neighbors), which is given by the following equation: 
n 
av.dist. = (1/n) ^Dic (equation 1) 
1=1 
where n is the number of neighbors within the cluster with center variant c. and Die is the 
genetic distance between variants i and c. Subsequent distinct clusters are found in the same 
manner as the first distinct cluster. 
The second and third menu options utilize the automatic algorithm described above and 
outputs the distinct clusters, the center genotype and its neighbors, the variants that belong to 
more than one cluster, and the variants that were not contained within any distinct clusters. 
The fourth menu option searches for sub-clusters within the distinct clusters. After an initial 
radius is chosen and the distinct clusters are displayed, the user can select a cluster and input a 
smaller radius to search for sub-clusters. The rearranged genetic distance mauix, menu option 
5. can be a useful tool to search for clusters and sub-clusters. Using a user-defined radius 
value, the genetic distance matrix is rearranged so that sequences clustered together are grouped 
together in the new distance mauix. The result is a symmetric matrix with small distances 
around the matrix diagonal and larger distances elsewhere (Fig. 1). 
In the final analysis of sequence clustering, there may be multiple clusters with different 
radius values. Menu options 6-9 o^er the user additional information that aids in defining the 
most representative clusters. For example, option 6 displays all the potential clusters rather 
than the algorithm-derived final clusters. Information concerning the average distance between 
the center genotype and all its neighbors can be obtained with menu option 7. The change in 
average distances may help to define appropriate radius values for different clusters. Menu 
options 8 and 9 provide information concerning distances between specific sequences. 
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Pseudocode 
input filename (includes numseq, numsites) 
choose to consider gaps in calculating sequence distances 
calculate Hamming distance between all pairwise sequence comparisons 
(store in distmatrix) 
sort the genetic distances 
output largest region of genetic distance not present in sorted list 
menu: 
1) display the genetic distance matrix 
output distmatrix 
2 )  display the clusters for a range of radius values 
input rmin and rmax 
for r = rmin, rmax (radius of cluster) 
for c = 1. numseq (center of cluster) 
identify variants within r of c 
for all centers and all radius values, store the number of variants within r of c and the 
average distance of all variants within r of c (eqn. I) 
for r = rmin, rmax (radius of cluster) 
for c = 1, numseq (center of cluster) 
identify distinct clusters as those with the most variants within r of c (if 
multiple clusters have the same number of variants, then choose the 
cluster with the smallest average distance of all variants within r of c); 
distinct clusters are not subsets of other clusters 
for r = rmin, rmax (radius of cluster) 
output the distinct clusters, including the center and all variants within r of the 
center, any variants that belong to more than one cluster, and all variants not 
contained within any clusters 
3) display the clusters for a single radius value 
same procedure as menu option (2), with rmin = rmax 
4) search a cluster for sub-clusters 
input r (radius) 
use the procedure for menu option (3) to find distinct clusters input clus^, the cluster to 
search for sub-clusters create a new genetic distance matrix for the variants within 
clus# use the procedure for menu option (3) to find distinct sub-clusters of C/MJ# 
output the variants that were contained within clusM and the distinct sub-clusters 
5) display a rearranged genetic distance mauix 
input r (radius) 
use the procedure for menu option (3) to find distinct clusters 
rearrange the genetic distance matrix so that variants within the distinct clusters are 
grouped together in the new genetic distance matrix 
output the new genetic distance matrix 
6) display ^  potential clusters for a single radius value 
input r (radius) 
for c = I, numseq 
identify and output all variants within r of c 
7) display the average distance for all centers in a range of radius values 
input rmin and rmax 
as in menu option (6), identify all potential clusters for each radius value 
for r = rmin, rmax 
for c = 1, numseq 
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output the average distance of c 
8) display all genetic distance from a single sequence 
input seq 
from the genetic distance matrix, output all genetic distance from seq 
9) display the genetic distance between two sequences 
input seqI 
input seq2 
from the genetic distance matrix, output the distance between seql and seq2 
Implementation 
CAGE has been tested with several data sets including human inununodeficiency virus 
type I (HIV-1) envelope sequences described by Shapshak et al. (13). The HIV-1 sequences 
consisted of the VI-V5 domains of the surface envelope gene (approximately 1129 bases) 
isolated from different regions of the brain. Sixty-three sequences from this study and another 
sequence (HIVHXB3), used as the outgroup (accession numbers AF125810-AF125874, 
M14100), were analyzed by CAGE. 
The nucleotide sequences were used to create the genetic distance matrix, ignoring gap 
positions (the analysis when gap positions were considered gave similar findings). After 
sorting the distance between all pairwise sequences comparisons, the program identified that no 
sequences differed by 69-107 nucleotide changes. Using menu option 3 with a radius value of 
69. three distinct, non-overlapping clusters were identified and designated Clusters A, B, and 
C. These clusters contained all the sequences except the outgroup sequence. Cluster A 
contained 41 variants, while Clusters 8 and C contained 13 and 9 variants, respectively. These 
results can be summarized by the rearranged genetic distance matrix, particularly using the 
graphical output of the windows based PC version of the program (Figure I). Clusters A. B, 
and C, identified by CAGE, corresponded to patients 144, 222, and 196, respectively, from 
which the envelope sequences were isolated. 
Using menu option 4 with an initial radius of 69, we searched for possible sub-clusters 
present in Clusters A, B, and C. In Cluster A, the program identified that no sequences 
differed by 26 or 27 nucleotide changes. Using a radius value of 26, four distinct, non-
overlapping sub-clusters were found that accounted for all but one variant within Cluster A. In 
Cluster B, a radius of 17 (identified by the program) found two distinct sub-clusters, where 
two sequences belonged to both sub-clusters. Two distinct, non-overlapping sub-clusters 
were identified in Cluster C using a radius of 9 (identified by the program). 
By simply using menu option 3 and the information about regions where no genetic 
distances were detected, three distinct, non-overlapping clusters were found that accounted for 
all sequences except the outgroup sequence. Using menu option 4, eight distinct sub-clusters 
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were found within the three main clusters. These 8 sub-clusters contained all but two variants, 
and 2 other sequences were shared by 2 of the sub-clusters. This broad picture of the clusters 
was further refined by utilizing menu options 5-9. For each cluster, smaller radius values were 
determined to maximize the compactness of the clusters. The final result of the cluster analysis 
show 5 sub-clusters in Cluster A, 3 sub-clusters in Cluster B, and 2 sub-clusters in Cluster C 
(Figure 2). Each of the sub-clusters corresponded to sequences that were isolated from the 
same region of the brain. Virus had been isolated from four different regions of the brain. In 
patient 144 (Cluster A), envelope sequences were amplified from all four regions. In the other 
patients, however, envelope sequences were recovered from only 3 regions in patient 222 
(Cluster B) and from only 2 regions in patient 196 (Cluster C). 
The genetic distance between the 3 large clusters was approximated by the distance 
separating centers of their respective sub-clusters. The genetic distance among Clusters A, B, 
and C was greater than ICX) nucleotide differences. The large genetic distances separating the 3 
clusters further supported the fact that the sequences in this data set had been isolated from 3 
different patients. The 5 sub-clusters in Cluster A had radius values ranging from 7 to 20 
nucleotide differences. In contrast, the range of radius values in the 3 sub-clusters of Cluster B 
was 4 to 6, and both sub-clusters of Cluster C had a radius value of 3. The genetic distance 
between sub-clusters of the major clusters was variable and was calculated as the distance 
between the center genotypes of each sub-cluster. The inter-cluster distance among sub-
clusters of Cluster A was generally around 50 nucleotide differences. In Cluster B, the inter-
cluster distance of the sub-clusters was around 25 nucleotide differences, and the 2 sub-
clusters of Cluster C were separated by 36 nucleotides (Figure 2). The genetic diversity within 
Cluster A was much greater than in the other two clusters, as reflected by the large inter-cluster 
distances and radius values of the Cluster A sub-clusters. This observation suggests that 
patient 144 (Cluster A) had been infected for a longer period relative to the other two patients. 
Shapshak also noted that the genetic divergence within brain regions was higher in patient 144 
and came to the same conclusion about the relative age of infection in patient 144. Overall, the 
results of our CAGE analysis agreed well with Shapshak's phylogenetic analysis. 
Discussion and conclusion 
The analysis offered by the CAGE program, as described in the previous section, is an 
intuitive means of clustering genetically similar variants. The genetic distance that separates 
sequences and clusters also provides an understandable quantitative tool for researchers 
studying genetic data. The minimal assumptions incorporated within the program do not rely 
on complex models of evolution or bifurcation between sequences. Thus, some data sets 
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which may not be well-suited to more complex methods may be analyzed well with CAGE. 
However, because of its minimal assumptions, CAGE cannot return the detailed analysis of 
genetic relationship like phylogenetic analysis can. The cluster analysis only finds groupings 
of sequences that are all similar rather than trying to define specific relationships between all 
sequences. The fact that our cluster analysis and the phylogenetic analysis gave similar results 
suggests that both analyses identified some biologically significant results. 
There are several layers of complexity involved with genetic data, and no single 
analytical tool can accurately describe the genetic and evolutionary relationships within the data. 
Multiple tools may be necessary to describe the genetic complexity. CAGE is an exploratory 
tool and is not meant to replace other genetic analysis tools, like phylogenetic reconstruction 
and multivariate statistical methods, but it should be used in conjunction with other tools to 
gain insight into how genetic sequences cluster together and how the variants are related. The 
main strengths of this program are its intuitive nature and its ability to explore several types of 
data. These strengths may best be utilized with newly attained data that is not well-
characterized, and/or is difficult to model. For example, CAGE has been used to analyze a 
longitudinal study of a viral regulatory gene that overlaps another open reading frame (in 
preparation). Multivariate statistical analysis of the data set was not beneficial, as the best 3-
dimensional representation of the data only captured approximately 50% of the information in 
the sequences. CAGE was used to characterize the clusters present at different time points and 
to study the evolution of the sequences and clusters over time. Other data sets that may not be 
well-suited to current methods of analyses may benefit from analysis by CAGE. 
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Figure 1. Screen-shot of the windows based CAGE program. The screen-shot on 
the left shows the original genetic distance matrix for the HIV-l brain data, with the darker 
squares indicating large genetic distances. A radius value of 69 was used to cluster the 
sequences, and the rearranged genetic distance matrix is shown on the right. In the rearranged 
distance matrix, the blue squares indicate small genetic distances, and the gray squares indicate 
large genetic distances. The rearranged matrix shows three distinct, non-overlapping clusters. 
Figure 2. Clusters of HIV-l env sequences isolated from the brain of infected 
patients. The ten clusters, represented by the circles, segregate according to the patients from 
which the sequences were isolated. The genetic distance between clusters in different patients 
(A) was much greater than the distance among clusters within patients. For each patient, the 
number of variants isolated from the patient is indicated. The numbers within each circle 
indicates the radius of the cluster (r) and the number of sequences within the cluster (n). 
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CHAPTER 4. EVOLUTION OF VIRAL QUASISPECIES IN VIVO: 
CO-EXISTENCE OF TWO DISTINCT POPULATIONS 
A paper to be submitted to the Proceedings of the National Academy of Sciences 
Prasith Baccam'", Michael Belshan'\ Gavin J. Naylor\ 
James Comette' and Susan Carpenter^ 
Abstract 
It has been known for some time that many viruses exist in vivo as a population of 
related, non-identical genotypes, commonly referred to as a quasispecies. Here, we have 
undertaken a longitudinal study to describe the quasispecies nature and genetic variation in a 
lentivirus regulatory protein. Rev, during the course of disease in a pony experimentally 
infected with equine infectious aneniia virus. This study examined Rev quasispecies in 
sequential sera samples by cloning and sequencing variants from each sample. Phylogenetic 
and cluster analyses suggested that the Rev quasispecies was comprised of two distinct 
populations that co-existed during infection. These two quasispecies populations differed in 
their pattern of evolution, with one population accumulating changes in a linear, time-
dependent manner, and the other population evolving radially from a common variant. At 
each time point, there were generally two quasispecies populations, with one predominant 
population and a minor population. Coinciding with changes in clinical disease, the minor 
population grew in size as the size of the major population diminished in a complementary 
manner. Rev variants from each population were biologically tested, and the results 
suggested that the two populations differed in biological phenotype. The results of this study 
suggest for the first time that viral quasispecies may co-exist as distinct quasispecies 
populations that may evolve independently and possess different selective advantages. A 
multi-population quasispecies model may have biologically significant implications on how 
viruses cause disease, contribute to the progression of disease, and develop variants resistant 
against antiviral drug therapy. Further studies will be necessary to determine whether 
multiple quasispecies populations co-exist in other viruses. 
' Department of Mathematics; Iowa State University 
• Department of Veterinary Microbiology and Preventive Medicine, Iowa State University 
^ Department of Zoology and Genetics, Iowa State University 
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Introduction 
Viruses that carry their genetic information in the form of RNA exhibit high mutation 
rales because the viral polymerase lacks proof-reading mechanisms commonly found in 
DNA polymerase complexes (32). The human immunodeficiency virus (HIV), for example, 
accumulates errors at the rate of 10'^ to 10"* per nucleotide site per replication (22. 27, 28). In 
conjunction with its high replication rate, approximately 10' virions produced daily (15), 
HIV exists as a population of closely related viral genotypes which are commonly referred to 
as quasispecies (9, 10, 16). Many other viruses have been shown to exist as a quasispecies 
population, including poliomyelitis virus, parvovirus, and rabies virus (4, 8, 25). A 
consequence of the genetic variation in viruses is the possibility of variation in viral 
phenotype of the quasispecies population. For example, HIV-1 variants isolated from the 
central nervous system (CNS) are genetically different from variants isolated from blood or 
from the spleen. In addition, these HIV-1 variants differed in their ability to infect the CNS 
and cause HIV dementia (26). HTV-l variants isolated from peripheral blood mononuclear 
cells (PBMC) also showed genetic and biological changes at different stages of disease (7). 
Changes in viral phenotype may be a biologically important factor in the progression of 
disease. For example, some individuals infected by HFV-l developed acquired 
immunodeficiency syndrome (AIDS) within months post-infection (31), while others can 
remain healthy and do not progress to AIDS more than 15 years post-infection (30). The 
differences in the rate of disease progression rely on both immune factors and viral factors. 
Viral quasispecies may be considered theoretically in terms of the population fitness. 
Biological fitness of a quasispecies is determined by the entire population, not simply by the 
fitness of a single sequence. The fitness of a quasispecies can be projected onto a "fitness 
landscape", as described by Wright (35), which represents selective pressures imposed by the 
host environment. Fitness on the landscape is represented by the elevation, with peaks 
representing fitness optima and valleys representing non-optimal fitness. The quasispecies 
population resides on the fitness landscape, where adaptive mutations are selected because 
they allow the quasispecies to climb up toward fitness peaks. Thus, the "selection 
equilibrium" found by a quasispecies population is only metastable (11); as more 
advantageous mutants arise, the previous equilibrium will collapse, and a new selection 
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equilibrium is achieved. In the HIV-1 example mentioned above, the organs infected by the 
virus can be represented by different fitness landscapes. Consequently, the viral quasispecies 
isolated from each organ have adapted to optimal peaks in each of the different fitness 
landscapes. Adaptation to optimal fitness peaks may result in biological phenotype changes 
which may be a factor in progression of disease. HIV-1 variants that infect the central 
nervous system, for example, may differ in neurovirulence and, thus, can impact progression 
towards AIDS. 
Because of the inter-connections between genetic variation, phenotypic variation, and 
disease, the goal of this study was to examine how a viral quasispecies evolved in a long term 
persistent infection and how those changes may have contributed to progression of disease. 
During the course of disease, the host environment and, therefore, the fitness landscape were 
not constant. The virus used in this study was equine infectious anemia virus (EIAV), a 
lentivirus which infects horses and produces a rapid and dynamic disease course (reviewed in 
(29)). The viral quasispecies examined in this study was the regulatory protein Rev, which is 
absolutely required for viral replication. Rev-attenuated phenotypes have been identified 
during asymptomatic stages of HIV-1 infection, suggesting that variation in Rev could alter 
virus replication levels and contribute to the clinical outcome of infection (17, 17, 20). We 
and others have observed genotypic and phenotypic variation in EIAV Rev (2, 3), suggesting 
that variation in the Rev quasispecies may be a factor in progression of disease. We present 
results that show the EIAV Rev quasispecies is characterized by two distinct populations of 
variants that co-existed during disease, evolved in different patterns, and differed in 
biological phenotype. 
Materials and methods 
Clinical Samples. The highly pathogenic Wyoming strain of EIAV was used to 
infect the study animal, pony 524, which underwent a disease course as described in (2). 
Briefly, this pony experienced 9 fever cycles through the first 135 days post infection (DPI), 
became afebrile and remained afebrile except for two late fevers at 565 and 799 DPI. The 
serum used to infect pony 524 and eleven sera samples taken from pony 524 during different 
stages of clinical disease were analyzed in this study. The sera samples included samples 
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from the initial acute febrile episode at 12 DPI and the intervening afebrile episode at 35 
DPI, three samples from the recurrent febrile stage, 67, 89, and 118 DPI, four samples from 
the afebrile stage, 201, 289, 385, and 437 DPI, and two samples from the late febrile stage, 
754, and 800 DPI (Figure 1). 
Genotypic and Phenotypic Characterization of Rev Variants. Virus was pelleted 
from sera samples by ultta centrifugation, viral RNA was isolated, amplified by RT-PCR, 
cloned, and individual clones were picked and sequenced. All rev sequences obtained in the 
study were aligned and translated into the predicted Rev amino acid sequences. Variants that 
differed at the amino acid level were identified by R# according to the order they appeared. 
Sixty-one clones were sequenced from the inoculum and approximately 24 clones were 
sequenced from each serum sample. To assay the biological activity. Rev variants were sub-
cloned into an EIAV Rev expression plasmid. Rev-mediated nuclear export activity was 
quantified in transient expression assays using a chloramphenicol acetyl transferase (CAT) 
reporter system as described in (3). 
Phylogenetic Analysis of Sequences. A total of 146 nucleotide variants, which 
corresponded to 101 Rev amino acid variants, were analyzed in the study. Phylogenetic 
analysis was used to characterize the genetic relationship among Rev amino acid variants. 
Two sequences, which had a single nucleotide insertion or deletion resulting in premature 
termination of the protein, were not included in the phylogenetic analysis. Overall, the Rev 
variants were closely related and did not differ greatly. Parsimony methods could not find 
distinct minimal trees, and maximum likelihood mediods were not feasible because of the 
large number of variants used in the study. Therefore, the neighbor-joining distance method 
was used to construct an unrooted phylogenetic tree from the Rev amino acid sequences 
using MEGA, version 1.01. The tree presented in this paper was calculated using the p-
distance method for estimating amino acid substitutions between clones. Other methods for 
estimating amino acid substitutions between clones, i.e. number of amino acid differences, 
Poisson-corrected distance, and gamma distance, were also used and resulted in nearly 
identical trees as the tree presented in this paper. 
Cluster Analysis of Sequences. The program CAGE (I) was utilized to group the 
rev nucleotide variants each time point. The analysis was designed to identify clusters of 
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closely related sequences using methods that maximized the number of variants contained 
within the cluster while minimizing the cluster radius and any overlap between clusters. The 
central genotype of each cluster is the sequence most representative of all variants within the 
cluster. 
Results 
The Viral Quasispecies Evolves Rapidly During Progression of the Disease. The 
viral quasispecies examined in this study was the regulatory gene rev. The Rev protein 
regulates expression of viral structural proteins and is absolutely required for virus 
replication. We and other labs have observed variation in the rev gene of EIAV, and earlier 
studies in our lab have shown that genetic variation in rev can significantly alter the 
biological activity of Rev in vitro (3). Therefore, variation in Rev quasispecies may play a 
role in progression of disease and viral persistence through restriction of viral gene 
expression. The isolation and sequencing of rev clones from an experimentally infected pony 
have been described (2). Briefly, the virulent Wyoming strain of EIAV was used to infect a 
pony, and sequential sera samples were collected from different stages of clinical disease. 
Viral RNA was isolated from the inoculum and from 11 sera samples, amplified, cloned, and 
individual clones were sequenced. All nucleotide sequences were aligned and translated into 
the Rev open reading frame. Amino acid variants were named in the order they were 
identified, with identical variants given the same name. For example, R1 was the Rev variant 
predominant in the inoculum and in the afebrile stage of disease. Described in detail in (2), 
the rev variants evolved rapidly, with frequent changes in the Rev quasispecies and 
consensus sequence over the course of disease. 
Neighbor*joining Tree Suggests Rev Variants Exist as Two Major Populations. 
A neighbor-joining uree was constructed to elucidate the genetic relatedness of the Rev amino 
acid variants and to study how they evolved. The different branching patterns of the 
resulting U'ee identiHed 2 major clades, designated Clade A and Clade B, and a minor clade, 
designated Clade C (Fig. 2). Within each of the clades, subclades could be identiHed that 
were comprised of genetically similar variants, with at most 3 amino acid differences 
separating variants in the subclade. Clades A and B contained variants from the inoculum as 
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well as variants from each stage of disease. In addition, all three clades contained Rev 
variants, such as Rl, R17 and R86, that were detected during more than one clinical stage of 
disease. Despite these overall similarities, there were marked differences in the genetic 
diversity within the clades and the pattern of evolution suggested by the clades. 
Major Clades Differ in Genetic Diversity and Pattern of Evolution. Clade A was 
comprised of seven subclades, denoted A1 through A7. Genetic variation within Clade A 
was large, with 8 amino acid differences between R3 and R94. Four of the seven subclades, 
A1-A4, were homogeneous: within each subclade, all variants were isolated from the same 
clinical stage. Subclades A3 and A4 consisted of sequences from the recurrent febrile stage 
(89 and 118 DPI). Subclade A2 branched from A3 and contained sequences from the 
afebrile stage (201 DPI). Finally, subclade A1 branched from A2 and was characterized by 
sequences from the late febrile stage (754 and 800 DPI) (Fig. 2). This branching pattern 
suggested that Rev variants in Clade A accumulated point mutations from pre-existing 
variants in a time-dependent, linear fashion. The temporal evolution was characterized by 
Rev variants that emerged and disappeared rapidly. 
In contrast, the genetic diversity observed in the other major clade, Clade B, differed 
dramatically from Clade A. The sequences in Clade B were genetically very similar, with 
only three amino acid differences between any two variants within the entire clade. In 
subclade B2, 19 of 21 variants differed from Rl by only one amino acid. These same 
variants were isolated from all different stages of disease and appeared to have evolved from 
a common variant, Rl, in a radial manner. 
The minor clade, Clade C, contained variants that were genetically diverse from all 
other sequences in the tree. The genetic diversity of Clade C was 8 amino acid differences, 
the same as Clade A, even though the number of variants in Clade C was only 12% of Clade 
A. The variants R3 and R94 in Clade A differed by 8 amino acids, with 5 of the 8 amino 
acid changes observed in previous Rev variants. In contrast, R5 and R81 were also separated 
by 8 amino acids changes in Clade C, but 5 of the 8 changes had never been observed prior to 
R8I. Thus, the origin and biological signiHcance of this subclade are uncertain. 
Distribution of Variants at Different Stages of Disease. The variable nature of EIA 
disease allowed us to compare Rev variants present at each stage. The stages of disease from 
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which the variants were isolated are as follows: the acute febrile stage, made up of the initial 
acute febrile episode and the intervening afebrile episode following it; the recurrent febrile 
stage, which is characterized by recurring cycles of fever and thrombocytopenia; the afebrile 
stage, and the late febrile stage, which surrounds the last fever of the pony. Interestingly, the 
variants in the 3 clades isolated were not distributed uniformly among the different stages of 
disease. During the recurrent febrile period 89.2% of Rev variants belonged to Clade A 
(Table 1). Likewise, the late febrile stage was predominated by variants from Clade A 
(66.6%). In contrast, the acute febrile stage was predominated by variants from Clade B 
(75.0%). The unequal distribution of Clade A and B variants at the different stages of 
disease suggested that the two major Rev populations differed in selective advantage at the 
different  s tages of  disease.  Thus,  Clade A variants  may have a  select ive advantage during 
the recurrent and late febrile periods, while Clade B variants may be selected for in the acute 
febrile stage of disease. 
Taken together, the phylogenetic analysis suggested that two or three distinct groups 
of Rev variants co-existed during the course of this particular disease case. Furthermore, the 
two major populations of variants, Clade A and Clade B, differed in genetic diversity, and in 
their pattern of evolution. 
The Rev Quasispecies Cloud May Exist as Multiple Populations. A cluster 
analysis was performed to investigate the quasispecies nature of Rev variants and whether 
the Rev quasispecies existed as two or more distinct populations. The temporal nature of the 
sequence data was exploited by using the program CAGE to cluster the rev nucleotide 
variants present at each time point. Briefly, each variant was used as the center of a cluster, 
and clusters were defined by a radius of nucleotide differences. From all the potential 
clusters, the optimal cluster was defined as that which maximized the number of variants 
contained within the cluster while minimizing the radius and any overlap between other 
clusters. Therefore, the central genotype of each cluster is the sequence that is most 
representative of the variants contained within the cluster. A radius of 3 nucleotide changes 
or less defined all of the clusters. While the radius value used to define the clusters was 
similar at all time points, the proportion of rev variants contained within the clusters was 
highly variable. To capture this information, the relative size of the clusters in Figure 3 was 
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used to represent the proportion of variants within each cluster rather than the radius used to 
define the clusters. The cluster analysis found that most time points could be characterized 
by 2 and sometimes 3, quasispecies clusters, designated as Clouds 1, 2, and 3 (Fig. 3). 
As the disease progressed, the relative size of the quasispecies clouds varied. 
reflecting changes in the relative proportion of variants belonging to the different 
quasispecies populations. For example, the proportion of variants from Cloud 1 was minor in 
the acute febrile stage, grew to predominate during the recurrent febrile stage, decreased 
during the afebrile stage, and re-emerged to predominate in the late febrile stage. In contrast, 
the proportion of variants from Cloud 2 was minor at the times when Cloud 1 variants were 
predominant and was predominant when Cloud I variants were minor (Fig. 3). The fact that 
changes in quasispecies cloud sizes coincided with changes in clinical stages of disease 
suggested that the Rev quasispecies clouds may have different selective advantages or 
occupy different selective niches. 
Evolution of Quasispecies Clouds. Since both the phylogenetic and cluster analyses 
suggested multiple quasispecies populations, we examined where individual variants 
belonged in the tree and in the clusters. It was found that variants grouped in the same 
quasispecies cloud were generally found in the same clade of the phylogenetic tree. Variants 
that belonged to Clouds I, 2, and 3 in the cluster analysis corresponded to variants that 
belonged to Clades A, B, and C, respectively, from the phylogenetic analysis. Early during 
infection, the distance between the center of the clouds was small, and the clouds intersected 
slightly. As the disease progressed, the clouds grew distinctly further apart (Fig. 3). The 
evolution of the quasispecies clouds during infection was examined by tracking the evolution 
of the central genotype of each cloud. The number of nucleotide differences between the 
central genotype and all other variants identified prior to that time point were compared. It 
was found that at each time point, the central genotype from each cloud evolved from 
variants belonging to the same cloud types in earlier time points, i.e. central variants from 
Cloud 1 evolved from variants from Cloud 1, and likewise for Cloud 2 and Cloud 3. The 
central genotype of Cloud 1 was highly variable over the course of infection, with 7 different 
variants in the 12 times points Cloud I was detected. In contrast, the central genotype of 
Cloud 2 was more stable, with R1 acting as the central genotype in 8 of the 10 times points 
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Cloud 2 was detected. These results further support the phylogenetic results showing that the 
variants in Cloud I evolved in a rapid and temporal manner while the variants in Cloud 2 
were genetically stable throughout infection. Furthermore, the evolution of the quasispecies 
clouds supports the notion that the clouds represent distinct quasispecies populations that 
may differ in selective niche advantage. 
Biological Activity of Rev Variants Differs. To determine whether the variants in 
the two quasispecies clouds had different selective advantages, the biological phenotype of 
Rev variants from each population was tested. A chloramphenicol acetyl u-ansferase (CAT) 
reporter system was used to quantitate the relative activity of Rev variants. The central 
genotype from each of the quasispecies clouds and some representative variants from the 
phylogenetic ttee were tested, and the results are summarized in Figure 4. All Rev activity 
were calculated relative to Rl, the variant which was the central genotype of Cloud 2 in 8 of 
10 time points, including the inoculum. All variants tested from Clade A/CIoud 1 had 
significantly higher Rev activity than Rl (p<0.02). The variants tested from Clade B/Cloud 
2 were more varied in their level of Rev activity, ranging from 66% (R26) to 180% (R51). 
Three of the four variants tested were found to have low Rev activity (<100%). Thus, the 
recurrent febrile and late febrile stages of disease were characterized by Rev variants from 
Cloud 1, which had 50-75% higher Rev activity than Rl. In contrast, the acute febrile and 
afebrile stages of disease were predominated by variants belonging to Cloud 2, which were 
characterized by the relatively low activity of Rl and R2. The sample at 201 DPI was 
characterized by the co-existence of Rev variants with low activity, Rl and R2, and some 
variants, R71 and R72, which had relatively higher activity. Thus, it appears that day 201 
post infection represents a transition between the recurrent febrile and afebrile stages of 
disease. These results suggest that the clinical stages of disease (recurrent febrile and late 
febrile stages) were predominated by variants with high Rev activity, whereas the acute 
febrile and afebrile stages were correlated with variants with low Rev activity. It appears that 
the Rev quasispecies clouds represent distinct quasispecies populations that occupy different 
selective niches. Furthermore, these distinct Rev quasispecies populations co-exist during 
disease, and the relative proportion of these quasispecies populations varied in response to 
changes in the selective host environment. 
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Discussion 
Both the phylogenetic and cluster analyses demonstrated that the Rev quasispecies 
existed as two major populations. The phylogenetic tree suggested the two quasispecies 
populations co-existed throughout the entire course of disease. In addition, these two 
populations evolved differently, with one population (Clade A) accumulating point mutations 
in a linear, time-dependent manner. The other major population (Clade B) consisted of Rev 
variants that were genetically similar and appeared to have evolved from a common variant 
in a radial manner. The cluster analysis focused on the Rev quasispecies at each time point 
and found that two major populations co-existed in each serum sample. The evolution of the 
quasispecies clouds during the course of disease supported the results of the phylogenetic 
uree. The Cloud 1 population continually evolved, with 7 different central genotypes in the 
12 times points Cloud 1 was detected. Like the genetically stable variants in Clade B, the 
central genotype of Cloud 2 was stable, with R1 acting as the central variant in 8 of the 10 
times points Cloud 2 was detected. In addition, the cluster analysis revealed that these two 
quasispecies populations grew and diminished in population size as the horse progressed 
through different stages of clinical disease, suggesting that these populations might have 
different selective advantages. Biological assays were used to test a number of Rev variants, 
and the results supported the supposition that variants in the two quasispecies had different 
selective advantages. Thus, the two quasispecies clouds could be considered distinct Rev 
quasispecies populations which differed in both genotype and phenotype. 
The concept of viral quasispecies was first introduced by Eigen and Schuster in 1977 
(II). The quasispecies "cloud" represents a population of heterogeneous, yet related viral 
genomes. Like a real cloud, the quasispecies population does not need to be synmietric, but 
there may be viral variants that stretch the boundaries of the cloud in search for better fitness. 
Many viruses, including bacteriophage <t)6, vesicular stomatitis virus, influenza virus, and 
HIV have been experimentally shown to exist as a quasispecies population (13, 18, 23, 34). 
The results of our studies suggest that the Rev quasispecies population may exist as multiple, 
distinct populations that evolve independently and differ in biological fitness. The most 
striking result of this smdy was that the two major Rev quasispecies possessed selective 
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advantages that appeared to complement each other. When one population was not well-
suited to the selective environment, the other population flourished. And when the 
environment changed to select against the latter population, the former population was well-
adapted for the new environment. 
The results of this study suggest for the first time that viral quasispecies may co-exist 
as distinct populations that may evolve independently and possess different selective 
advantages. With respect to a fitness landscape, these results suggest that there may be 
multiple, distinct quasispecies populations occupying different regions of the landscape. 
According to the competitive exclusion principle, one population will always out-compete 
the other in the absence of niche differences (12). Our results do not violate this principle, as 
our analyses clearly indicate that the two major quasispecies populations possessed different 
selective niches. Because they occupied different selective niches, the distinct quasispecies 
populations could co-exist as the disease progressed. 
The number of distinct populations within a viral quasispecies Is never explicitly 
mentioned in discussions about quasispecies. Differences between a single viral quasispecies 
and multiple co-existing quasispecies populations could be evaluated by how each model 
would predict the effect of a change in the host environment. A model with a single viral 
quasispecies would predict some lag time after a change in the fitness landscape before 
adaptive mutations could accumulate in the quasispecies population and move the population 
toward a new fitness peak. On the other hand, the co-existence of multiple quasispecies 
populations in different regions of the fitness landscape would allow the virus to adapt 
rapidly to changes in the host environment by expanding minor populations which may be 
near the new fitness peaks. Aside from our study, the co-existence of multiple quasispecies 
populations may be supported by the evolution of drug-resistant viral variants, as is observed 
for HIV, hepatitis B virus, and herpes virus (14, 19, 24). Resistance of HTV-l variants to the 
RT inhibitor ATZ (also known as ZDV), for example, has been associated with 4 mutations 
in the viral RT polymerase. These mutations are usually accumulated sequentially and are 
not detected until several months post-treatment (5), suggesting that these resistant variants 
arose de novo. HTV-I variants resistant to lamivudine (3TC), on the other hand, require only 
a single mutation to confer resistance (21) and can be detected within weeks of 3TC therapy 
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(33). It is likely that viral quasispecies harbor these drug resistant variants as minor 
populations even in ureatment-naive patients (6). 
By randomly sampling approximately 24 clones per time point, our results suggest 
there may be two major Rev quasispecies and a minor quasispecies population. Given the 
high rate of replication and the high degree of variation in viruses, it is reasonable to extend 
these results to viruses with multiple quasispecies populations that co-exist during the course 
of infection. The existence of multiple quasispecies populations with different biological 
fitness may explain how viruses adapt so quickly to changes in the host environment. This 
study represents the quasispecies population detected in a pony experimentally infected with 
EIAV, and further studies of viral quasispecies will be necessary to determine whether 
multiple quasispecies co-exist in other viruses. 
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Table 1. Distribution of Clade A, B, and C variants at 
different stages of disease 








A 37.5 25.0 89.2 46.7 66.6 
B 54.2 75.0 10.8 36.7 16.7 
C 8.3 0.0 0.0 16.6 16.7 
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Figure 1. Clinical disease of pony 524. The vertical bars represent the temperature of the 
pony during the course of disease, with clinical fever defined as temperatures over 101°F. 
Sera samples were taken from each of the time points shown above. 
Figure 2. Neighbor-joining tree of the Rev amino acid variants. The tree naturally 
divides into 3 clades, designated Clades A. B. and C. Within each clade, several subclades 
were defined. The stage of disease from which the Rev variants were isolated is indicated by 
the color of its branch. Variants isolated from multiple stages of disease are indicated by 
multi-colored branches. The Rev variants accented by yellow boxes were biologically tested 
for Rev activity. 
Figure 3. The cluster analysis of rev nucleotide variants. The clusters present at each 
time point were found using the program CAGE. The relative size of each cluster represents 
the proportion of variants contained within the cluster. Clusters that overlap indicate that 
both clusters share at least one variant. Variants in the same cluster were generally found in 
the same clade of Figure 2. The central variant for each cluster is shown, and the color of the 
cluster corresponds to the clade from which most variants were found. The different clusters 
were designated Cloud 1 (yellow). Cloud 2 (blue), and Cloud 3 (red). The arrows show 
which cluster the central variant likely evolved from. 
Figure 4. The Rev activity of variants from different quasispecies clouds. All activity is 
reported relative to the activity of Rl. Variants that differed significantly from the activity of 
Ri are indicated, with p-values represented by (*) p<0.05, (**) p<0.005, and (***) 
p<0.(XXX)5. 
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CHAPTER 5. GENERAL CONCLUSION 
The combination of a high error rate, a small genome, and a high rate of replication 
produces virus that exist as a population of related genomes commonly called a viral 
quasispecies (4, 5, 8). A consequence of the genetic variation is variation in viral phenotype, 
which can contribute to the progression of disease. The work presented here examined viral 
variation in a single animal during a persistent infection. The goal of this study was to 
investigate genetic and biological variation in the Rev quasispecies and their contribution to 
the pathogenesis and persistence of equine infectious anemia virus (EIAV) in an 
experimentally infected pony. Our sampling of viral variants from sequential time points 
post infection represents one of the most comprehensive longitudinal studies of viral 
variation to date. Analyses of the genetic and biological variation of Rev variants have shed 
light on the quasispecies nature of Rev variants, the evolution of Rev quasispecies, and how 
the Rev quasispecies may contribute to EIAV persistence. These results may be extended to 
other retroviruses and to viruses in general. 
Genetic variation in Rev during disease 
Previous studies have identified extensive nucleotide substitutions in the EIAV rev 
open reading frame both in vivo and in vitro (1, 10). Rather than simply identifying variation 
in rev, the work presented here sought to examine how genetic variation in rev during the 
course of disease might affect EIAV persistence. Consequently, the number of variants 
sampled at each time point in this study was 3-5 fold higher than the sampling in a previous 
study (10). In addition, our study included sera samples taken from the clinically inapparent 
stage of disease, which had not been done in previous studies. The genetic variation 
described in Chapter 2 illustrated the rapid and dynamic changes in rev during the course of 
disease. Novel variants appeared rapidly and continually evolved, and some variants grew in 
frequency to predominate the Rev quasispecies. The entire Rev quasispecies population 
changed during infection, as evidenced by the changes in the consensus sequences. The re­
appearance of the predominant variant in the inoculum, Rl, later during disease was a novel 
finding. An HIV study claimed that the founder virus re-emerged later in the course of 
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disease (9). This result, however, came from direct sequencing of virus amplification and 
may not represent sequences of individual viral clones. 
Co-existence and evolution of Rev quasispecies populations 
Both the phylogenetic and cluster analyses described in Chapter 4 suggested the co­
existence of two distinct EIAV Rev quasispecies populations. The phylogenetic tree 
suggested that all the variants observed throughout the course of disease could be grouped 
into 2 major clades and a minor ciade. The two major quasispecies populations differed in 
their pattern of evolution, with one population accumulating changes in a linear, time-
dependent manner, and the other population evolving radially from a common variant. The 
cluster analysis grouped sequences in each time point that were genetically similar and found 
that each time point during disease was characterized by two and sometimes three clusters of 
variants. Changes in the population size of these Rev quasispecies populations coincided 
with changes in clinical disease and further suggested that the different populations possessed 
different selective advantages. 
Statistical correlation between Rev quasispecies activity and EIA disease 
Results of the phylogenetic and cluster analyses suggested that Rev variants from the 
two quasispecies populations may differ in selective advantage. Rev variants from each of 
the quasispecies populations were biologically tested, as described in Chapter 2. Variants 
that predominated during the recurrent febrile and late febrile periods had significantly higher 
Rev activity than the variants that predominated the acute febrile episode and the afebrile 
period. Experimental and predicted Rev activity for the quasispecies population were 
calculated and used to test for correlation with clinical signs of disease. The statistical 
analyses described in Chapter 2 found that Rev quasispecies activity was statistically 
correlated with temperature of the pony. Furthermore, the Rev quasispecies activity in the 
acute febrile stage and the afebrile stage were statistically different from the activity in the 
recurrent febrile stage. Together, these results provide strong evidence that variation in the 
regulatory protein Rev is associated with viral pathogenesis and persistence. This study adds 
support to previous studies which have suggested that variation in viral regulatory proteins 
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may contribute to viral persistence through down-regulation of viral gene expression (2, 10, 
11). 
Future studies 
The results of this study have contributed to our current understanding of genetic and 
biological variation in EIAV Rev. Furthermore, the suggestion that Rev quasispecies co­
exist as multiple, distinct populations challenges the current thinking of viral quasispecies. 
The longitudinal design of this study allowed us to examine Rev variation during the course 
of disease. The drawback of this study, however, is the fact that the variation was observed 
in only one animal. In order to extend the findings of this study to EIAV in general, similar 
studies will be necessary in additional animals. Likewise, similar studies in other viruses will 
be necessary to determine whether the co-existence of distinct quasispecies with different 
selective niches is common among viruses. 
Sampling from different stages of clinical disease allowed us to smdy genetic and 
biological differences of Rev variants present at different stages of disease. The differences 
observed in this viral regulatory protein helped to explain how EIAV can persist in the face 
of an active immune response. Immune factors, such as virus specific CTL and neutralizing 
antibody responses, have been associated with resolution of the initial febrile episode and the 
recurrent febrile stage, respectively. However, no specific subset of the immune response 
has been correlated with conu-ol of virus replication during long term persistence (6). 
Likewise, no subset of the immune response has been correlated with resolution of individual 
fever cycles in the recurrent febrile stage. A study of Rev variation within the recurrent 
febrile stage would require more detailed sampling. Virus would need to be isolated from 
each fever cycle and each intervening afebrile cycle. The results of such a study may help to 
identify viral and host factors that contribute to selection during the recurrent febrile cycles. 
The fact that the major rev open reading frame (ORF) is completely overlapped by 
the transmembrane envelope {gp45) ORF raises questions concerning selection for nucleotide 
changes within this region. A single nucleotide change in this overlapping region could 
produce an amino acid change in one ORF, both ORFs, or neither ORF. The Tajima test (12) 
of this rev/gp45 region found that mutations in this region were due to positive selection 
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rather than neutral mutations. The ratio of non-synonymous and synonymous nucleotide 
changes in both the rev and gp45 ORFs was greater than one, suggesting positive selection in 
both ORFs. It would be nice to be able to predict whether a specific nucleotide change in the 
overlapping region was advantageous to one ORF or the other. Such predictions may be 
possible by using amino acid similarity matrices such as the PAM or BLOSUM matrices (3, 
7). Similarity matrices indicate the likelihood that one amino acid will change to another 
amino acid. Since current similarity matrices were derived from sequences with single 
ORFs, these matrices may not be well-suited for regions that encode overlapping ORFs. 
Therefore, a similarity matrix would need to be derived using only sequences that encode 
multiple ORFs. Such a matrix specifically for overlapping OElFs may help to determine 
which reading frame is affected by nucleotide changes, such as in the rev/gp45 region. 
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APPENDIX. STATISTICAL ANALYSIS OF PRIMER PAIR BIAS 
Introduction 
Genetic variation in viral genomes has been implicated in contributing to viral 
persistence, pathogenesis, immune evasion, and disease progression (3, 11, 18). 
Consequently, molecular characterization of virus present in vivo during natural infections 
can provide insight into factors important in viral pathogenesis and disease progression. True 
characterization, however, is difficult to ascertain because of quasispecies nature of viruses 
(4, 5, 7). 
A potential problem with current methods used to characterize viral quasispecies is 
the possible selection of a sub-population of quasispecies that may not be reflective of the 
population present in vivo. For example, virus isolated following cell culture growth may be 
subject to selective pressures atypical of those which occur in a natural, in vivo infection. 
The frequency of observed viral genotypes in samples taken directly from blood can differ 
from distributions obtained following growth in cell culture (9). Moreover, the selective 
processes can also markedly change the viral phenotype [2108, 5726,5723}. The selective 
processes involved in culturing virus has prompted the development and use of alternative 
methods that rely on genetic analysis of virus populations taken directly from biological 
samples. Typically, these methods amplify viral templates using reverse transcriptase-
polymerase chain reaction (RT-PCR) or PCR; the amplicon is inserted into a plasmid vector, 
cloned into a bacterial host, and individual clones are sequenced (15). The underlying 
assumptions are that all viral variants are amplified with equal efficiency and that the 
resulting proportions are representative of proportions in the starting material. While these 
assumptions have been generally accepted, some reports suggest that PCR amplification 
might result in selective amplification of individual templates, especially in reactions 
containing a mixture of templates (1,6, 13, 16, 17). 
Here, we examined the effect of different primer pairs on the identity and distribution 
of the rev gene of equine infectious anemia virus (EIAV). The results will allow us to 
determine whether the sampled viral populations were reflective of populations in vivo. The 
viral templates were isolated directly from serum, amplifled by RT-PCR, cloned, and 
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sequenced. Four different oligonucleotide primer pairs were used during PCR amplification 
and were examined for evidence of systematic bias in the sampled population. 
Statistical analyses 
A two-dimensional chi-square test was used to test the null hypothesis that the 
frequency distribution of observed variants and the choice of primer pairs was independent. 
Cells of the contingency tables contained the frequency of experimental observations and the 
expected frequency. Expected frequencies were calculated as the product of the row total 
and column total for that cell, divided by the overall number of observations. The chi-square 
statistic was calculated, and the p-value was determined for each contingency table. The 
statistical threshold used in this study was 95% confidence. Subset pairwise analyses were 
also performed on the data, and the results were interpreted with Bonferroni's correction 
(10). Subsequently, the p-values for the 6 pairwise analyses were compared to 0.0083 rather 
than 0.05 for confidence at the 95% confidence level. 
A Monte Carlo computer simulation (14) was done to corroborate the results of the 
chi-square tests. For the comparison of the four primer pairs together, 10 variants were 
randomly created for each set of (simulated) primer pairs. The variants were created with 
identical proportions in each set of primer pairs, e.g. the proportion of R1 was set to 30% in 
each set of primer pairs. The chi-square distance between the four simulated sets was 
calculated. This entire procedure was simulated 10,000 times. The experimentally observed 
chi-square distance was compared to the 10,000 simulated distances to find the percentile 
ranking which correlates to the p-value. For the pairwise analyses of primer pairs, 10 
variants were randomly created for each set of the two (simulated) primer pairs. The rest of 
the simulation was the same as described inunediately above, except the Kullback distance 
(2) was used rather than the chi-square distance. 
no 
Results 
Identity and distribution of viral variants. To determine whetiier primer pairs have 
a systematic effect on the distribution of observed variants, four different sets of primer pairs 
were used to amplify Rev sequences from viral RNA (Table 1). The oligonucleotide primers 
were designed in the most conserved regions flanking rev. A total of 40 individual clones, 
ten from each primer pair amplification, were sequenced from a single EIAV serum sample 
(Table 2). At the nucleotide level, 28 different genotypes were observed and were designated 
Q l  t h r o u g h  Q 2 8 .  O n l y  f i v e  g e n o t y p e s  w e r e  o b s e r v e d  a t  a  f r e q u e n c y  g r e a t e r  t h a n  o n e ;  Q l ,  
Q2, Q3, Q4, and Q5. These results are consistent with other studies which have shown EIAV 
to exhibit a highly heterogeneous quasispecies population (8, 12). The amplified region of 
EIAV contains two overlapping reading frames, one coding for the cytoplasmic portion of 
the transmembrane envelope protein and the other coding for the regulatory protein Rev. For 
this study, our analysis of variation at the amino acid level is restricted to the Rev open 
reading frame. There were 20 different Rev variants, designated R1 through R20, with only 
3 variants found at a frequency greater than one. Those three, designated Rl, R2, and R3, 
made up 30%, 17.5%, and 10% of the sample population, respectively. The frequencies 
observed clearly demonstrate that the distribution of observed viral variants was not 
uniformly random. 
Effects of primer pairs on quasispecies distribution. Five nucleotide variants, Ql 
through Q5, and three Rev variants, Rl, R2, and R3, were the only variants observed with 
frequencies greater than one. Therefore, the statistical analyses tested the null hypothesis 
that the frequency distribution of these variants and all other variants was independent from 
the choice of primer pairs. The chi-square test did not detect any statistically significant 
differences due to the use of different primer pairs at either the nucleotide or amino acid level 
(p=0.31 and p=0.35, respectively) (Table 3). Similar results (p=0.25) were obtained when 
R3 was grouped with the other minor Rev variants (not shown). The lack of significant bias 
due to primer pair choice suggests that the observed quasispecies population is reflective of 
the in vivo population. 
The observed ratios of Rl to R2 were markedly different in some primer pair 
comparisons. For example, the R1:R2 ratio was 5:0 with primer pair 3 and 2:4 with primer 
l i t  
pair 4 (Table 3). In fact, the contingency ceils for RI and R2 of primer pairs 3 and 4 
contributed the most to the chi square test statistic (not shown). Therefore, chi-square 
analysis was performed using a pairwise comparison of primer pairs (Table 4). Using 
Bonferroni's correction for the six pairwise analyses, no statistical significance was detected 
among any of the pairwise analyses at either the nucleotide level or the protein level. These 
findings support the chi-square analysis of the four primer pairs together and suggest that the 
primer pairs are not affecting the frequency of observed variants. 
Computer simulations support the results of the chi-square analyses. In the 
majority of cells in the contingency tables, the value of the expected frequency was less than 
five, which is generally lower than is desired for chi-square analysis. Because it was not 
practical to generate sufficient numbers experimentally, computer simulations were used to 
evaluate the validity of the chi-square analyses. A Monte Carlo procedure was designed to 
simulate four sets of primer pairs with 10 quasispecies each, and 10,000 replicates of data 
were generated from a multinomial distribution with identical proportions. The comparison 
of all four primer pairs produced p-values of 0.30 and 0.36 at the nucleotide and protein 
levels, respectively. Simulations were also performed to check the pairwise chi-square 
analyses (Table 4). Again, the p-values derived from the simulations were very similar to the 
p-values obtained by chi-square analyses. Together, these results indicate a good correlation 
between the observed and simulated p-values. 
Discussion 
The goal of this study was to determine whether different primer pairs used in PCR 
might systematically alter the frequency distribution of viral variants obtained through 
random sampling of a single serum sample. Ten individual clones were sequenced from each 
amplification, and chi-square analyses were used to determine whether the frequency of 
observed variants and choice of primer pairs was independent. When all four primer pairs 
were tested together, no statistical significance was detected due to the use of different 
primer pairs at either the nucleotide or amino acid level (p=0.31 and p=0.35, respectively). 
In pairwise comparisons of primer pairs, using Bonferroni's correction, all six analyses were 
non-significant at the nucleotide and protein level. To partially alleviate the danger of failing 
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to reject independence due to small sample size and the asymptotic nature of the chi-square 
test, Monte Carlo computer simulations were conducted to generate 10,000 replicates of data 
as a check of the p-values obtained by the chi-square tests. The results of the chi-square 
analyses were fully corroborated by Monte Carlo computer simulations. Together, these 
results suggest that the viral population obtained from random sampling was unaffected by 
primer pair choice and can be considered reflective of in vivo populations. 
While other studies have suggested that primer pairs may systematically bias PCR 
amplification (1, 13, 17), they have generally involved 2 or 3 different templates of known 
concentrations. The complex quasispecies nature of virus in vivo complicates similar studies. 
Despite these complexities, our data shows that the primer pairs used during PCR 
amplification did not alter the frequency of observed variants. Design of the primers to 
conserved target sequences may have reduced risk of bias. In addition, similar GC-content 
and optimal annealing temperature between the four primer pairs (Table 1) may also have 
reduced risk of bias during PCR amplification. Taken together, the results of this study 
suggest that randomly sampled viral populations can be reflective of in vivo populations. 
This lends some confidence to the characterization of viral populations present in vivo, which 
leads to better interpretations of studies involving viral persistence, pathogenesis, immune 
evasion, and disease progression. 
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Table 1. Primer pairs used for amplification of EIAV Rev sequences 
Primer Primer Primer GC O.A.T.'' 
Pair Name* Sequence (S'-3') content(%) ("O 
EM 7066 CAATTTGGCACAATCCATGA 40 
1 EM 7674C' GCGAGAGTTCCTTCTTGGGC 60 55.7 
EM 7066 CAATTTGGCACAATCCATGA 40 
2 EM 7680CR1 GGAATTCCGAGAGTTCCTTCTTGG 50 55.7 
E M 7 i 6 0  GGATTGGGAGCTTCCATTAT 45 
3 EM 7674C' GCGAGAGTTCCTTCTTGGGC 60 55.5 
EM 7160 GGATTGGGAGCTTCCATTAT 45 
4 EM7680C'R1 GGAATTCCGAGAGTTCCTTCTTGG 50 55.5 
® C indicates the primer is on the complementary (anti-sense) strand, and R1 indicates that 
an Eco R1 restriction site was added to the 3' end. 
'' Optimal annealing temperature for PCR amplification, as calculated by the program Oligo 
5.1 (Plymouth, MN). 
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^ Different nucleotide sequences were designated as Q#. 
" Different amino acid sequences translated in the Rev open reading frame were designated 
R#. 
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Table 3. Contingency table for the chi-square analysis* of observed viral population 
amplified with different primer pairs 
Primer Pair 
12 3 4 
obs" (exp)" obs"* (exp)" obs^ (exp)" obs" (exp)" 
Qi 0 (1) I ( 1 )  3 ( I )  0 ( 1 )  
Q2 1 ( 1 )  0 ( 1 )  2 ( i )  I ( I )  
Nucleotide Q3 I (1) I ( 1 )  0 ( 1 )  2 ( I )  
Variants Q4 0 (0.8) 2 (0.8) 1 (0.8) 0 (0.8) 
Q5 0 (0.5) 1 (0.5) 0 (0.5) I (0.5) 
Others'"" 8 (5.7) 5 (5.7) 4 (5.7) 6 (5.7) 
R1 2 (3) 3 (3) 5 (3) 2 (3) 
Amino Acid R2 1 (1.8) 2 (1.8) 0 (1.8) 4 (1.8) 
Variants R3 1 ( I )  2 ( 1 )  1 ( 1 )  0 ( I )  
Others'"" 6 (4.2) 3 (4.2) 4 (4.2) 4 (4.2) 
Number of times observed. 
Expected frequency, calculated as the product of row total and column total, divided by 
overall total of clones sampled. 
' All other variants combined. 
* The chi-square analyses detected no statistical difference in the distribution of quasispecies 
due to the use of different sets of primer pairs at the nucleotide level (p=0.31) or at the 
protein level (p=0.35). 
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Table 4. Pairwise analyses testing independence of primer pairs and the frequency 
distribution of observed variants* 
Primer pairs Nucleotide Protein 
analyzed Variants Variants 
CS'' MC" CS" MC" 
1 and 2 0.34 0.14 0.65 0.68 
1 and 3 0.25 0.42 0.27 0.22 
1 and 4 0.65 0.44 0.27 0.25 
2 and 3 0.36 0.46 0.29 0.25 
2 and 4 0.49 0.27 0.61 0.64 
3 and 4 0.17 0.13 0.07 0.05 
P-values derived from chi-square analysis. 
'' P-values derived from Monte Carlo simulation. 
* Using Bonferroni's correction, these p-values are compared to 0.0083 for interpretations at 
the 95% confidence level. Thus, none of the pairwise analyses is statistically significant. 
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